<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81646</article-id><article-id pub-id-type="doi">10.7554/eLife.81646</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-285817"><name><surname>Song</surname><given-names>Jinyeop</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4113-5185</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-285387"><name><surname>Jeong</surname><given-names>Bo-Seong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0629-6722</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285818"><name><surname>Kim</surname><given-names>Seong-Woo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4374-2093</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285819"><name><surname>Im</surname><given-names>Seong-Bin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1488-6386</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-315851"><name><surname>Kim</surname><given-names>Seonghoon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-315852"><name><surname>Lai</surname><given-names>Chih-Jen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285820"><name><surname>Cho</surname><given-names>Wonki</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-235280"><name><surname>Jung</surname><given-names>Jae U</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-285821"><name><surname>Ahn</surname><given-names>Myung-Ju</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-11266"><name><surname>Oh</surname><given-names>Byung-Ha</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6437-8470</contrib-id><email>bhoh@kaist.ac.kr</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05apxxy63</institution-id><institution>Department of Physics, Korea Advanced Institute of Science and Technology</institution></institution-wrap><addr-line><named-content content-type="city">Daejeon</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05apxxy63</institution-id><institution>Department of Biological Sciences, KAIST Institute for the Biocentury, Korea Advanced Institute of Science and Technology</institution></institution-wrap><addr-line><named-content content-type="city">Daejeon</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Cancer Biology Department, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q78tk20</institution-id><institution>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Department of Physics, Massachusetts Institute of Technology, Cambridge, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81646</elocation-id><history><date date-type="received" iso-8601-date="2022-07-06"><day>06</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-05-11"><day>11</day><month>05</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-07-13"><day>13</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.12.499671"/></event></pub-history><permissions><copyright-statement>© 2023, Song, Jeong et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Song, Jeong et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81646-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81646-figures-v1.pdf"/><abstract><p>Immunoglobulin G (IgG) antibodies are widely used for diagnosis and therapy. Given the unique dimeric structure of IgG, we hypothesized that, by genetically fusing a homodimeric protein (catenator) to the C-terminus of IgG, reversible catenation of antibody molecules could be induced on a surface where target antigen molecules are abundant, and that it could be an effective way to greatly enhance the antigen-binding avidity. A thermodynamic simulation showed that quite low homodimerization affinity of a catenator, <italic>e.g</italic>. dissociation constant of 100 μM, can enhance nanomolar antigen-binding avidity to a picomolar level, and that the fold enhancement sharply depends on the density of the antigen. In a proof-of-concept experiment where antigen molecules are immobilized on a biosensor tip, the C-terminal fusion of a pair of weakly homodimerizing proteins to three different antibodies enhanced the antigen-binding avidity by at least 110 or 304 folds from the intrinsic binding avidity. Compared with the mother antibody, Obinutuzumab(Y101L) which targets CD20, the same antibody with fused catenators exhibited significantly enhanced binding to SU-DHL5 cells. Together, the homodimerization-induced antibody catenation would be a new powerful approach to improve antibody applications, including the detection of scarce biomarkers and targeted anticancer therapies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>IgG antibody</kwd><kwd>antibody catenation</kwd><kwd>avidity enhancement</kwd><kwd>new technology</kwd><kwd>antibody application</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id>http://dx.doi.org/10.13039/100020144</institution-id><institution>Samsung</institution></institution-wrap></funding-source><award-id>SRFC-MA2002-06</award-id><principal-award-recipient><name><surname>Oh</surname><given-names>Byung-Ha</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetically fusing weakly homodimerizing proteins to the C-terminus of IgG antibodies to induce reversible catenation on a target surface greatly enhances antigen-binding avidity, offering a promising approach for a range of antibody applications.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Immunoglobulin G (IgG) antibodies have become the principal therapeutic biologic. IgG antibodies are a homodimer of a heterodimer composed of two copies of each heavy chain (~50 kDa) and light chain (~25 kDa). They have two functional regions: the antigen-binding fragment (Fab) region at the N-terminal end and the fragment crystallizable (Fc) region at the C-terminal end. With an overall shape of the letter Y, the two identical regions of Fab form two arms that can bind two antigen molecules. This antibody-antigen engagement could prevent the antigen from binding to cognate partners or eliminate the antigen molecules from the cell surface by receptor-mediated endocytosis (<xref ref-type="bibr" rid="bib22">Liu, 2018</xref>). The two copies of Fc form a homodimeric tail that enables a long half-life via binding to the neonatal Fc receptor (FcRn) and exerts effector functions via binding to the Fcγ receptors on effector immune cells or the complement factor C1q (<xref ref-type="bibr" rid="bib12">Hogarth and Pietersz, 2012</xref>; <xref ref-type="bibr" rid="bib19">Lee et al., 2017</xref>), which could lead to the death of cells to which antibody molecules are bound (<xref ref-type="bibr" rid="bib3">Carter and Lazar, 2018</xref>; <xref ref-type="bibr" rid="bib8">Goydel and Rader, 2021</xref>; <xref ref-type="bibr" rid="bib16">Jiang et al., 2011</xref>).</p><p>IgG antibodies have desirable properties for use as a therapeutic drug, including high specificity for a target antigen, low immunogenicity and long serum half-life (<xref ref-type="bibr" rid="bib35">Weiner et al., 2010</xref>). On the other hand, therapeutic monoclonal antibodies (mAbs) show side effects, albeit to a lesser degree in comparison with conventional chemotherapeutics, such as low or high blood pressure and kidney damage (<xref ref-type="bibr" rid="bib10">Hansel et al., 2010</xref>). In the case of targeted cancer therapy, where mAbs target a specific antigen on cancer cells, the side effects likely arise due to the expression of the target antigen not only on cancer cells but also on normal cells, which therefore are targeted indiscriminately by mAbs administered in patients (<xref ref-type="bibr" rid="bib28">Scott et al., 2012</xref>). Moreover, mAbs often suffer from shortcomings such as moderate therapeutic efficacy (resulting in the development of resistance) and their efficacy in a fraction of patients (as observed for mAbs against immune checkpoint inhibitors; <xref ref-type="bibr" rid="bib1">Aldeghaither et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Hansel et al., 2010</xref>; <xref ref-type="bibr" rid="bib34">Wang et al., 2021</xref>). Insufficient blockade of target antigens for various reasons, including insufficient antigen-binding affinity, could be responsible for the moderate therapeutic efficacy.</p><p>In general, diagnostic and therapeutic antibodies are required to exhibit low nanomolar or higher antigen-binding affinity (<italic>K</italic><sub>D</sub> &lt;10 nM) (<xref ref-type="bibr" rid="bib30">Sliwkowski and Mellman, 2013</xref>). To reach this level of affinity, laborious experiments for affinity maturation are usually followed after an initial discovery of an antibody (<xref ref-type="bibr" rid="bib13">Hoogenboom, 2005</xref>). Increasing the valency of binding interaction could be a method of choice. It was shown that irreversibly dimerized monovalent binders can bind targets significantly better than monomeric counterparts (<xref ref-type="bibr" rid="bib6">Foreman and Vilar, 2017</xref>). This enhancement of the binding affinity arises from the proximity effect, where the binding of one subunit of the dimer to a target restricts the search space for the other subunit. Reversibly dimerized binders could also exhibit significantly enhanced binding affinity depending on the affinity for binder-target interaction, affinity for homodimerization and the length of the connecting linker, as predicted by a reacted-site probability approach (<xref ref-type="bibr" rid="bib6">Foreman and Vilar, 2017</xref>). Such approaches to increase the valency of binding have been applied to IgG antibodies, and a considerable increase in the antigen-binding affinity was observed in vitro (<xref ref-type="bibr" rid="bib36">White et al., 2014</xref>). However, as the size of an IgG-type antibody is large (~150 kDa), irreversible cross-linking or tight reversible dimer formation of the antibody would result in poor solubility and tissue penetration in vivo.</p><p>Owing to the overall dimeric structure, IgG antibodies genetically fused to a homodimeric protein at the C-terminus can be catenated in an arm-in-arm fashion as long as the homodimer can be formed, not within an antibody molecule, but between two antibody molecules. In theory, it would be possible to generate a soluble fusion protein that remains monomeric in solution, but becomes catenated by the proximity effect on a cell surface where target antigen molecules are abundant, provided that the fused protein has appropriately low homodimerization affinity. Importantly, this proximity effect-driven catenation, in turn, should result in enhanced bivalent antigen-binding affinity (=avidity). In this work, by agent-based modeling (ABM) and proof-of-concept experiments, we demonstrate that antibody catenation induced by intermolecular homodimerization can enormously enhance the antigen-binding avidity of an antibody on a target surface.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The concept of antibody catenation on a target surface</title><p>This concept was based on (i) the unique dimeric structure of the IgG-type antibody and (ii) a proximity effect that potentially takes place on a target cell surface. In the structure of IgG, the Fc domain is composed of two copies of the constant regions of the heavy chain (C<sub>H2</sub> and C<sub>H3</sub>) forming a homodimer, in which the two C-termini are ~23 Å apart and point away from each other (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <italic>Left</italic>). This structural feature indicated that a homodimer-forming protein genetically fused to the C-terminus can be prevented from forming a homodimer intramolecularly by controlling the length of the connecting linker or its homodimerization affinity. Instead, the fusion protein can form a homodimer intermolecularly, and then such a homodimerization could result in a catenation of the antibody molecules (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <italic>Right</italic>). We designate the fusion protein between an antibody and a homodimeric protein as antibody-catenator (<sup>cat</sup>Ab). A proximity effect for <sup>cat</sup>Ab is expected on a target surface where multiple copies of target antigen are present, because the local concentration of <sup>cat</sup>Ab on the surface will increase owing to the antibody-antigen binding interaction. Consequently, the homodimerization between the catenator molecules will increase to form catenated antibodies in an arm-in-arm fashion (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Importantly, the effective antigen-binding affinity of <sup>cat</sup>Ab will increase in parallel with the catenation, and the fold enhancement would depend on the degree of the catenation. Thus, it appeared possible to enhance the antigen-binding avidity of the IgG-type antibodies by genetically fusing a weakly homodimer-forming protein.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The concept of antibody catenation on a target surface by fusion of a catenator.</title><p>(<bold>A</bold>) Molecular model for catenator-fused antibodies. A flexible linker (Gly-Gly-Ser) between Fc and the catenator and the hinge segment between Fc and Fab were modeled by using the ROSETTA software. The catenator is an α-helical hairpin that forms four-helix anti-parallel coiled coils (PDB entry: 1ROP). The structure of Fc was derived from the IgG1 antibody (PDB entry: 1IGY) and that of Fab from an antibody against the receptor-binding domain of the SARS-CoV-2 spike protein (PDB entry: 6XE1). (<bold>B</bold>) Decreased dissociation by antibody catenation. Pairs of <sup>cat</sup>Ab-antigen complexes adjacent to each other can be catenated, and the <sup>cat</sup>Ab molecules are increasingly harder to dissociate from each other with increased catenation. The effective antigen-binding avidity would increase owing to a decreased off rate of <sup>cat</sup>Ab.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Agent-based modeling to simulate the behavior of <sup>cat</sup>Ab</title><p>ABM is a computational modeling approach that has been employed in a variety of research areas, including statistical physics (<xref ref-type="bibr" rid="bib26">Perc et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Fu and Wang, 2008</xref>) and biological sciences (<xref ref-type="bibr" rid="bib2">An et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Metzcar et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">McLane et al., 2011</xref>). ABM enables the understanding of macroscopic behaviors of a complex system by defining a minimal set of rules governing microscopic behaviors of agents which compose the system.</p><p>We constructed an ABM to simulate the behavior of the <sup>cat</sup>Ab molecules on a target surface, where target antigen (Ag) molecules form antibody-binding sites. To circumvent complexity, we presumed that each binding site is a pair of two antigen molecules (2Ag), and <sup>cat</sup>Ab make a bivalent interaction with the binding site in a 1:1 stoichiometry to form an occupied binding site (<sup>cat</sup>Ab-2Ag; <xref ref-type="fig" rid="fig2">Figure 2A</xref>, <italic>Left</italic>). For catenation to occur between two adjacent <sup>cat</sup>Ab-2Ag complexes, the distance between the centers of two adjacent complexes (<italic>d</italic>) should be closer than the reach length (<italic>L</italic>) defined as <italic>l+c</italic>/2, the sum of the linker length (<italic>l</italic>) and the half the catenator length (<italic>c</italic>) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <italic>Right</italic>). Therefore, multiple parameters affect the catenation on the target surface. In our ABM model, we regarded every possible binding site on the target surface as an individual agent in the ABM formalism, and each binding site is assigned to a fixed position on a three-dimensional (3D) surface with a periodic boundary condition. Three rules in our ABM govern the behaviors of the <sup>cat</sup>Ab molecules on the target surface. The first rule is about the <italic>intrinsic antibody-antigen binding</italic>. An unoccupied binding site binds to one free <sup>cat</sup>Ab through bivalent interaction to form an occupied binding site. Bound <sup>cat</sup>Ab may dissociate from the occupied binding site, leaving the binding site unoccupied. The equilibrium population of the occupied and unoccupied binding sites is determined by the antibody’s intrinsic avidity for the antigen with no effect of the catenator on the antigen-binding avidity assumed. Then, the relative likelihood of the occupied state compared to the unoccupied state for any binding site (the likelihood of intrinsic antigen binding) is defined as [<sup>cat</sup>Ab-2Ag]/[2Ag] and thus can be expressed as [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub>, where [<sup>cat</sup>Ab] is the concentration of <sup>cat</sup>Ab and <italic>K</italic><sub>D</sub> is the dissociation constant for the bivalent <sup>cat</sup>Ab-2Ag interaction (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <italic>Left</italic>). The second rule is about <italic>catenation</italic>. A pair of <sup>cat</sup>Ab-2Ag complexes on the target surface can be bridged by intermolecular homodimerization between catenators (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <italic>Middle</italic>). For a pair of <sup>cat</sup>Ab-2Ag complexes separated by <italic>d</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <italic>Right</italic>), the relative likelihood of the catenation state as compared to the non-catenation state is the ratio of the forward reaction rate (catenation) to the reverse reaction rate (decatenation). The forward reaction rate (<italic>R</italic><sub>catenation</sub>) and the reverse reaction rate (<italic>R</italic><sub>decatenation</sub>) are given as,<disp-formula id="equ1"><mml:math id="m1"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi> </mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mi>*</mml:mi><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>*</mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi></mml:math></disp-formula><disp-formula id="equ2"><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mi>*</mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>ABM for simulating the binding dynamics of a catenator-fused antibody.</title><p>(<bold>A</bold>) (<italic>Left</italic>) Each binding site is composed of two antigen molecules (2Ag). (<italic>Right</italic>) The gray circles indicate the sphere sampled by the catenator, and <italic>V</italic><sub>overlap</sub> is the overlapping volume between the adjacent spheres. Catenation between two <sup>cat</sup>Ab molecules is possible only in <italic>V</italic><sub>overlap</sub>. (<bold>B</bold>) The three rules of the ABM model. (<italic>Left</italic>) <sup>cat</sup>Ab-2Ag binding occurs with a relative likelihood, [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub>. (<italic>Middle</italic>) The catenation between adjacent <sup>cat</sup>Ab-2Ag complexes occurs with an indicated relative likelihood, <italic>f</italic>(d)/(<italic>K</italic><sub>D</sub>)<sub>Catenator</sub>, determined by (<italic>K</italic><sub>D</sub>)<sub>Catenator</sub> and the inter-complex distance <italic>d</italic>. (<italic>Right</italic>) It was assumed that <sup>cat</sup>Ab molecules that are catenated do not dissociate from the surface. (<bold>C</bold>) The simulation requires specification of the parameters for the binding site, antibody and catenator. Through the MCMC sampling, the state of binding sites on the target surface is iteratively updated with the ABM rules and eventually sampled. A sufficient number of sampling results are collected to quantify the binding occupancy and the effective dissociation constant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Calculation of <italic>f(d</italic>) using uniform local density approximation.</title><p>(<bold>A</bold>) Definition of parameters and the equation of <italic>f(d</italic>). The forward catenation rate at which two catenators dimerize is proportional to the volumetric overlap (<italic>V</italic>(<italic>d</italic>)) between the effective concentration of the catenator, which is assumed to be uniformly distributed over a sphere defined by the reach length (L). <italic>V</italic>(<italic>d</italic>) depends on the distance (d) between the two adjacent <sup>cat</sup>Ab-2Ag complexes as well as the reach length. (<bold>B</bold>) Plot of <italic>f(d)</italic> as a function of d calculated for the indicated reach length (L).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Simulation data for catenation enhancement by binding sites interval and linker length in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig2-figsupp1-v1.tif"/></fig></fig-group><p>, where <italic>k</italic><sub>f</sub> and <italic>k</italic><sub>r</sub> are the reaction rate constant of the forward and reverse reaction, respectively, <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the Avogadro number, <italic>V</italic><sub>sphere</sub> is the local spherical volume within the reach of the catenator, and <italic>V</italic><sub>overlap</sub>(<italic>d</italic>) is the volume where two catenators can come in contact to form a homodimer (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <italic>Right</italic>). In approximating the forward reaction rate, the catenator was assumed to sample <italic>V</italic><sub>sphere</sub> uniformly. The relative likelihood, defined as <italic>R</italic><sub>catenation</sub>/<italic>R</italic><sub>decatenation</sub>, is then expressed as<disp-formula id="equ3"><mml:math id="m3"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>*</mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>*</mml:mi><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>where<disp-formula id="equ4"><mml:math id="m4"><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>*</mml:mi><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>The relative likelihood is thus a function of <italic>d</italic>, and it is inversely proportional to the dissociation constant of the catenator in the bulk medium, (<italic>K</italic><sub>D</sub>)<sub>catenator</sub>. The function <italic>f</italic>(<italic>d</italic>) can be viewed as the effective local concentration of the catenator in <italic>V</italic><sub>overlap</sub>(<italic>d</italic>). As expected, <italic>f</italic>(<italic>d</italic>) and thus the relative likelihood is sensitively affected by the reach length and limited by the <sup>cat</sup>Ab-<sup>cat</sup>Ab distance (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Finally, the third rule is about <italic>restricted dissociation</italic> which assumes that catenated antibodies are not allowed to dissociate from the binding site, because the catenated arms would hold the dissociated antibody near its binding site, forcing it to rebind immediately (<xref ref-type="bibr" rid="bib21">Liese and Netz, 2018</xref>). Under this assumption, antibody molecules are allowed to dissociate from the binding site, only if its catenator is not engaged in the homodimerization with nearby <sup>cat</sup>Ab-2Ag complexes (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <italic>Right</italic>).</p></sec><sec id="s2-3"><title>Simulations show significant enhancement of the antigen-binding avidity</title><p>According to the postulated rules, we simulated the effects of the antibody catenation on the binding interaction between <sup>cat</sup>Ab and 2Ag on a three-dimensional surface by using the Markov Chain Monte-Carlo (MCMC) sampling method (<xref ref-type="bibr" rid="bib14">Hooten and Wikle, 2010</xref>) (see Methods section). Our sampling procedure is composed of three steps (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The first step is an <italic>initialization</italic>, where a target surface with the antibody-binding sites is defined by specifying the coordinates for each site. A set of binding sites are positioned equidistant from each other or randomly positioned, and the inter-site distance or the number of binding sites were set as variables. The next step is an <italic>MCMC stochastic update</italic> step. In each iteration, a binding site is randomly selected from the target surface, and the probability of changing the status of the selected binding site (occupied or not) is calculated by the Metropolis-Hasting algorithm (<xref ref-type="bibr" rid="bib11">Hastings, 1970</xref>; <xref ref-type="bibr" rid="bib9">Grazzini et al., 2017</xref>). Then, the ‘on’ or ‘off’ state of this site is updated with the calculated probability. Accordingly, the catenation state is probabilistically updated for each update step. In the following sampling step, the total number of the occupied binding sites is counted, which is then collected through multiple simulation runs for the statistical analysis of the binding site occupancy and the effective antigen-binding avidity. The binding site occupancy is the mean value of the number of occupied binding sites collected for more than 1024 MCMC samplings. For each simulation, we calculated the mean binding occupancy and the effective dissociation constant, (<italic>K</italic><sub>D</sub>)<sub>eff</sub>, which takes into account the effect of the antibody catenation, and is expressed as:<disp-formula id="equ5"><mml:math id="m5"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi> </mml:mi><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi> </mml:mi><mml:mi>O</mml:mi><mml:mi>c</mml:mi><mml:mi>c</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mo>)</mml:mo><mml:mi>*</mml:mi><mml:msup><mml:mrow><mml:mo>[</mml:mo></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi> </mml:mi><mml:mi>S</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi> </mml:mi><mml:mi>O</mml:mi><mml:mi>c</mml:mi><mml:mi>c</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Since the catenator homodimerization should be affected by how the binding sites are distributed on a 3D surface, simulations were conducted for different arrays of binding sites. In the simulations, (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> was the main variable, while other parameters were set constant. First, we simulated the binding sites forming a square lattice to find that the Ab-catenator exhibited enhanced binding site occupancy in a sigmodal manner, and that it could be enhanced to near full saturation by a catenator that forms a homodimer with quite low binding affinity. For instance, a <sup>cat</sup>Ab with (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> of ~1 μM exhibited ~70-fold enhancement of the effective antigen-binding avidity (=reduction of (<italic>K</italic><sub>D</sub>)<sub>eff</sub>) in comparison with the same antibody without a fused catenator (<xref ref-type="fig" rid="fig3">Figure 3</xref>). As a means of comparison across different simulation setups, we employed ‘(<italic>K</italic><sub>D</sub>)<sub>catenator,50</sub>’ which is defined as the (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> that enables half-maximal enhancement of the binding site occupancy (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Simulations of the binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub> in response to (<italic>K</italic><sub>D</sub>)<sub>catenator</sub>.</title><p>(<italic>Left</italic>) Binding site occupancy. The simulations were carried out for a square array of the binding sites. The values for a set of variables were <italic>K</italic><sub>D</sub> = 10<sup>–8</sup> M, [<sup>cat</sup>Ab]=10<sup>–9</sup> M, reach length = 7 nm, spacing between the binding sites = 12 nm and the number of total binding sites = 98. The mean value and standard deviations of 1024 MCMC simulations for each (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> value are shown in blue, and the data are shown as a scatter plot of representative runs (orange). (<italic>Right</italic>) The effective dissociation constant. The data shown on the left were converted into the (<italic>K</italic><sub>D</sub>)<sub>eff</sub> values. The dashed line represents the <italic>K</italic><sub>D</sub> value for the same antibody without a catenator. The maximum fold enhancement of the effective binding avidity, which is equivalent to the reduction of (<italic>K</italic><sub>D</sub>)<sub>eff</sub>, is 70.6.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Simulation data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig3-v1.tif"/></fig></sec><sec id="s2-4"><title>Comparison of the simulations for different arrays of the binding sites</title><p>Next, we carried out simulations for other regular arrays of the binding sites and for randomly distributed binding sites. Depending on the pattern of regularly distributed binding sites, the number of possible catenations for a given binding site (designated as connectivity number) varies: 3, 4 and 6 for a hexagonal, square or triangular array of the binding sites, respectively (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These three arrays showed varying but similar enhancement of the binding site occupancy and the effective antigen-binding avidity by the catenator (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As expected, the higher the connectivity number was, the lower (<italic>K</italic><sub>D</sub>)<sub>catenator,50</sub> an array exhibited; the (<italic>K</italic><sub>D</sub>)<sub>catenator,50</sub> was 8.0, 9.2 and 12.2 µM for the hexagonal, square and triangular array of the binding sites, respectively. The simulations showed that, as the connectivity number increased, the effective antigen-binding avidity increased with the maximum 41-, 73-, and 93-fold enhancement for the triangular, square and hexagonal array, respectively (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Thus, regardless of the distribution patterns, the effective antigen-binding avidity could be increased by at least 41 folds under the simulation conditions where the target surface contains only 98 binding sites.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Simulations for different arrays of the binding sites.</title><p>(<bold>A</bold>) Comparison for regularly distributed binding sites. Three different regular arrays of the binding sites are shown at the top. The black dots represent the binding sites and the gray lines the connectable pairs by the catenators. The red circles and the blue lines represent the maximum range of catenation and the connectivity number, respectively, for a given binding site. Binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub> in response to (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> are shown at the bottom. 1024 trials were sampled for each (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> value and the results are plotted. The variables were <italic>K</italic><sub>D</sub> = 10<sup>–8</sup> M, [<sup>cat</sup>Ab]=10<sup>–9</sup> M, reach length = 7 nm, spacing between the binding sites = 12 nm, and the number of total binding sites were 98 for the square array and 102 for hexagonal and triangular array, respectively. The numbers on the right are the maximum fold enhancement of the effective binding avidity for each array. (<bold>B</bold>) Comparison for randomly distributed binding sites. Three random arrays of the binding sites with different binding site densities (ρ) are shown at the top. The surface area for the simulation was 5760 nm<sup>2</sup>. The simulation conditions were the same as in (<bold>A</bold>). Binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub> in response to (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> are plotted as in (<bold>A</bold>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Simulation data for regularly spaced binding sites in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Simulation data for irregularly spaced binding sites in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Simulations for randomly distributed, high-density binding sites.</title><p>1024 trials were sampled for each (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> value at the indicated density and the results are plotted. The variables were <italic>K</italic><sub>D</sub> = 10<sup>–8</sup> M, [<sup>cat</sup>Ab]=10<sup>–9</sup> M, reach length = 7 nm, spacing between the binding sites = 12 nm, and the surface area = 5760 nm<sup>2</sup>. The maximum fold enhancement of the effective binding avidity and (<italic>K</italic><sub>D</sub>)<sub>catenator,50</sub> are tabulated at the bottom.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Simulation data for binding sites with high density in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Values of the simulation data for binding sites with high density in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig4-figsupp1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Influence of the likelihood of intrinsic antigen binding ([<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub>) on binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub>.</title><p>(<bold>A</bold>) The binding occupancy and (<bold>B</bold>) the effective dissociation constant (<italic>K</italic><sub>D</sub>)<sub>eff</sub> in response to [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub> for [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub> = 1.0, 0.3, 0.1, 0.03, 0.01, where [<sup>cat</sup>Ab] was fixed to 10<sup>–9</sup> M and <italic>K</italic><sub>D</sub> was varied from 10<sup>–8</sup> to 10<sup>–6</sup>. The simulations were carried out with a square array of the binding sites as in <xref ref-type="fig" rid="fig3">Figure 3</xref>. The set values for the variable parameters were reach length = 7 nm, spacing between the binding sites = 12 nm and the number of total binding sites = 98. The mean binding occupancy of 1024 MCMC simulations was plotted. (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> was varied from 1 mM to 10 nM. The antibody binding avidity is substantially enhanced across a broad range of [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub>.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Simulation data for varying likelihood of intrinsic antigen binding in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-81646-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Influence of [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub> on binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub>.</title><p>(<bold>A</bold>) The binding occupancy and (<bold>B</bold>) the effective dissociation constant (<italic>K</italic><sub>D</sub>)<sub>eff</sub> in response to [<sup>cat</sup>Ab] for (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> = 1, 10, 100 μM. <italic>K</italic><sub>D</sub> was set to 10 nM, and [<sup>cat</sup>Ab] was varied from 0.1 to 10 nM. The simulations were carried out essentially the same as for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig4-figsupp3-v1.tif"/></fig></fig-group><p>For the case of randomly distributed binding sites on a 3D surface, which is relevant to target antigen distribution on cell surfaces, we introduced the binding site density (ρ), the number of binding sites per unit area which is set to the square of the reach length (7 nm; <xref ref-type="fig" rid="fig4">Figure 4B</xref>). In the simulations, the total surface area was 5760 nm<sup>2</sup>, and the number of binding sites was 15, 30, 45, 90, or 120, which correspond to the ρ of 1.47, 2.94, 4.41, 8.82, or 11.76. Denser binding sites would increase the connectivity number for a given binding site. As expected, simulations showed that higher binding site density resulted in a higher level of binding site saturation and a much more significant increase in the effective antigen-binding avidity; the maximum fold enhancement ranged from 15 (ρ=1.47)–1062 (ρ=11.76). Likewise, significantly different (<italic>K</italic><sub>D</sub>)<sub>catenator,50</sub> values were observed: for example, 4.2x10<sup>–6</sup> M at the ρ of 11.76 <italic>vs</italic> 74x10<sup>–6</sup> M at the ρ of 1.47 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The maximal saturation and the onset (<italic>K</italic><sub>D</sub>)<sub>catenator</sub>, which begins to exert the catenation effect, were also considerably different. Thus, the catenation effects are sensitively affected by the binding site density, in contrast with the all-or-none catenation effect observed for the regular arrays of the binding sites (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In particular, the catenation-induced enhancement of the antigen-binding avidity was remarkably and sensitively affected by the (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> values at high binding site density (ρ&gt;4.41; <xref ref-type="fig" rid="fig4">Figure 4B</xref>). Much greater enhancement was observed as we further increased the density of randomly distributed binding sites:~29,000 maximum fold enhancement at the ρ of 58.8 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), which roughly corresponds to two-hundredths of the density of the HER2 receptor on HER2-overexpressing breast cancer cells (<xref ref-type="bibr" rid="bib25">Peckys et al., 2019</xref>). Together, our simulations show that randomly distributed binding sites at high density enormously enhance the effective antigen-binding avidity of <sup>cat</sup>Ab.</p><p>Additionally, we performed simulations for different values of [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub> to estimate the effect of <italic>K</italic><sub>D</sub> with respect to [<sup>cat</sup>Ab]. Varying [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub> from 0.01 to 1.0 (by varying <italic>K</italic><sub>D</sub> from 10<sup>–8</sup> to 10<sup>–6</sup>) resulted in 85- to 900-fold enhancement of the antigen-binding avidity, suggesting that the catenation effect works for a broad range of <italic>K</italic><sub>D</sub> values (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). We also performed simulations to estimate the effect of [<sup>cat</sup>Ab]. Varying [<sup>cat</sup>Ab] from 0.1 to 10 nM resulted in far less than a 100-fold increase of (<italic>K</italic><sub>D</sub>)<sub>eff</sub>, showing that the enhancement of (<italic>K</italic><sub>D</sub>)<sub>eff</sub> by increasing the concentration of <sup>cat</sup>Ab is much less dramatic than that by increasing the affinity for catenator homodimerization (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p></sec><sec id="s2-5"><title>Proof-of-concept experiments</title><p>For experimental validation, we chose stromal cell-derived factor 1α (SDF-1α) as a catenator. SDF-1α is a small (Mr = 8 kDa) and weakly homodimerizing protein (<italic>K</italic><sub>D</sub> = 150 µM; <xref ref-type="bibr" rid="bib33">Veldkamp et al., 2005</xref>). Initially, by using a 10-residue connecting linker, (G<sub>4</sub>S)<sub>2</sub>, SDF-1α was fused to the homodimeric heavy chain (H chain) of two different antibodies: Trastuzumab(N30A/H91A), a variant of the clinically used anti-HER2 antibody Trastuzumab and a germline-encoded glCV30, an antibody against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The Fab fragment of Trastuzumab(N30A/H91A) binds to the ectodomain of HER2 with a <italic>K</italic><sub>D</sub> of 353 nM (<xref ref-type="bibr" rid="bib29">Slaga et al., 2018</xref>), and glCV30 binds to the RBD with a similar binding affinity (not avidity, <italic>K</italic><sub>D</sub> = 407 nM; <xref ref-type="bibr" rid="bib15">Hurlburt et al., 2020</xref>). Both antibody-catenator constructs exhibited drastic enhancements of the (<italic>K</italic><sub>D</sub>)<sub>eff</sub> for the target proteins immobilized on the biosensor surface. However, as described below in the ‘incidental observations’ section, we now believe that these constructs likely formed reversible heterogeneous oligomers in solution, and the resulting data would not be a correct reflection of the effect of antibody catenation.</p><p>It was possible to obviate the oligomerization problem by dually fusing a pair of two different catenators, SDF-1α and SAM, to the knobs-into-holes heterodimeric Fc (HetFc) (<xref ref-type="bibr" rid="bib18">Leaver-Fay et al., 2016</xref>), via a (G<sub>4</sub>S)<sub>2</sub> linker. The sterile alpha motif (SAM) domain of SLy1 is also a small (Mr = 7.4 kDa) and weakly homodimerizing protein (<italic>K</italic><sub>D</sub>=117 μM; <xref ref-type="bibr" rid="bib17">Kukuk et al., 2019</xref>). Fusion of the homodimeric proteins to HetFc would also result in the antibody catenation on a target surface in a fashion shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>, while their catenation efficiency would be reduced compared with a corresponding homodimeric antibody-catenator construct. Employing a HetFc is instrumental to generate a control antibody, which has a single catenator. This construct can at best form a dimer, but cannot be catenated (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; Right).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Catenation effect on the binding avidity.</title><p>(<bold>A</bold>) By employing a heterodimeric Fc (HetFc), an antibody fused to two different catenators (<italic>Left</italic>) or an antibody with one catenator arm (<italic>Right</italic>) can be generated. Only the former could form catenated antibodies on a surface where target antigens are abundant. (<bold>B</bold>) Elution profile and BLI analyses of Trastuzumab(N30A/H91A) and SAM-Trz(2 m)/HetFc-SDF-1α. Trz(2 m)/Het stands for Trastuzumab(N30A/H91A) with its homodimeric Fc replaced by a HetFc. The two heavy chains were fused to SAM or SDF-1α. The two antibodies were eluted from a size-exclusion column as if they were monomeric (<italic>Left</italic>). Elution positions of the size marker proteins are indicated by triangles. BLI runs for the two antibodies are shown (<italic>Right</italic>). The ectodomain of HER2 was immobilized on the biosensor tip. (<bold>C</bold>) Elution profile and BLI analyses of glCV30 and SAM-glCV30/HetFc-SDF-1α. The two antibodies were analyzed as described in (<bold>B</bold>). Commonly for all BLI runs, the experimental signals and fitted curves are shown in red and black, respectively. For curve fitting, 1:1 binding was assumed. The kinetic parameters are shown in the insets. <italic>k</italic><sub>a</sub>, association rate constant; <italic>k</italic><sub>d</sub>, dissociation rate constant. The experiments were performed in triplicates, and representative sensorgrams are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig5-v1.tif"/></fig><p>By replacing the original heavy chain with two heavy chains containing the ‘knobs’ or ‘holes’ mutations fused to SAM or SDF-1α, we first generated SAM-Trastuzumab(N30A/H91A)/HetFc-SDF-1α (in short, SAM-Trz(2 m)/HetFc-SDF-1α) and SAM-glCV30/HetFc-SDF-1α (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). While the heterodimer formation was not 100%, it was possible to purify the heterodimeric antibodies homogenously that exhibited a single elution peak from a size-exclusion column that corresponds to the size of the heterodimer (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Trastuzumab(N30A/H91A) and SAM-Trz(2 m)/HetFc-SDF-1α exhibited similar association kinetics in bio-layer interferometry (BLI) experiments: the association rate constants (<italic>k</italic><sub>a</sub>s) of the two antibodies were 1.9x10<sup>5</sup> Ms<sup>–1</sup> and 2.9x10<sup>5</sup> Ms<sup>–1</sup>, respectively. In contrast, the dissociation rate constants (<italic>k</italic><sub>d</sub>s) of the two antibodies were significantly different: 2.2x10<sup>–4</sup> Ms<sup>–1</sup> <italic>versus</italic> &lt;1.0 × 10<sup>–7</sup> Ms<sup>–1</sup>. As a result, SAM-Trz(2 m)/HetFc-SDF-1α exhibited the <italic>K</italic><sub>D</sub> less than 0.01 nM (the limit of the instrumental sensitivity), at least 110-fold higher binding avidity compared with that of Trastuzumab(N30A/H91A) (<italic>K</italic><sub>D</sub> of 1.1 nM; <xref ref-type="fig" rid="fig5">Figure 5B</xref>). These observed kinetics are consistent with the expectation that fused catenators would not affect the association of the antibodies, but would slow down the dissociation of the antibodies into the bulk solution via catenation of the antibody molecules on the sensor tip. The glCV30 and SAM-glCV30/HetFc-SDF-1α pair also exhibited similar association and dissociation kinetics, and the catenator fusion increased the binding avidity by at least 130 folds (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><p>To prevent the avidity enhancement beyond the instrumental sensitivity limit, we constructed triply mutated Trastuzumab(N30A/H91A/Y100A)/HetFc, which exhibited reduced binding avidity (<italic>K</italic><sub>D</sub> of 243 nM for HER2) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>; <italic>Bottom Left</italic>). The two catenator arms were fused to this antibody, and mScarlet to the light chain (for later cell-based experiments) to generate SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc-SDF-1α (L-mScarlet) (in short, SAM-Trz(3 m)/HetFc-SDF-1α (L-mScarlet)). For a control experiment, SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc (L-mScarlet) was generated that contains a single catenator arm. The two antibody-catenator constructs behaved as if they were monomeric in solution (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <italic>Top</italic>). BLI analyses showed that Trastuzumab(N30A/H91A/Y100A) and SAM-Trz(3 m)/HetFc-SDF-1α (L-mScarlet) exhibited similar association kinetics, but significantly different dissociation kinetics. As a result, SAM-Trz(3 m)/HetFc-SDF-1α (L-mScarlet) exhibited the <italic>K</italic><sub>D</sub> of 0.8 nM, 304-fold higher binding avidity compared with that of Trastuzumab(N30A/H91A/Y100A) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <italic>Bottom Middle</italic>). In support of the view that the observed avidity enhancement arises from the catenation of antibody molecules, SAM-Trz(3 m)/HetFc (L-mScarlet), which has one catenator arm and thus cannot catenate the antibody molecules (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), exhibited high dissociation kinetics and the <italic>K</italic><sub>D</sub> of 373 nM, which are close to those of the mother antibody (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <italic>Bottom Right</italic>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Catenation effects were observed for low-affinity mother antibodies.</title><p>(<bold>A</bold>) The triply mutated Trastuzumab(N30A/H91A/Y100A), the antibody with two catenator arms (SAM-Trz(3 m)/HetFc-SDF-1α) and the same antibody with one catenator arm (SAM-Trz(3 m)/HetFc) were prepared with their light chain (L) fused to mScarlet at the C-terminus. The two antibody-catenators were eluted from a size-exclusion column as if they were monomeric (<italic>Left</italic>). The SDS-PAGE of the peak fractions shows the correct sizes of the indicated chains (<italic>Right</italic>). BLI was performed similarly as described in <xref ref-type="fig" rid="fig5">Figure 5B</xref>. The two catenator-armed antibody exhibits a significant increase in the binding avidity, but the one catenator-armed antibody did not (<italic>K</italic><sub>D</sub> values in the inset). (<bold>B</bold>) Obnutuzumab(Y101L) and SAM-Obz(Y101L)/HetFc-SDF-1α were prepared, and BLI was performed with biotinylated human CD20 immobilized on the biosensor tip (<italic>Top</italic>). Flow cytometric analyses of SU-DHL5-binding by the two antibodies were performed (<italic>Bottom</italic>). For this experiment, the two antibodies were labeled with muGFP at the C-terminus of the light chain. The fluorescent signal from muGFP was detected by using a 525/40 bandpass filter.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>SDS-PAGE result for SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc-SDF1a and SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81646-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Purification of SAM-Obz(Y101L)/HetFc-SDF-1<sup>α</sup>.</title><p>Elution profile and SDS-PAGE analysis of SAM-Obz(Y101L)/HetFc-SDF-1α.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>SDS-PAGE result for SAM-Obinutuzumab(Y101L)/HetFc-SDF1a.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81646-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Another antibody with intentionally reduced binding avidity was constructed: Obinutuzumab(Y101L), a mutant version of the clinically used anti-CD20 antibody (<xref ref-type="bibr" rid="bib5">Evans and Clemmons, 2015</xref>). In our measurement, Obinutuzumab(Y101L) exhibited the <italic>K</italic><sub>D</sub> of 30.4 nM for CD20 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Also generated was SAM-Obinutuzumab(Y101L)/HetFc-SDF-1α (in short, SAM-Obz(Y101L)/HetFc-SDF-1α), which was monomeric in solution (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). This antibody/antibody-catenator pair also exhibited similar association kinetics, but significantly different dissociation kinetics: <italic>k</italic><sub>a</sub>s were 3.3x10<sup>5</sup> Ms<sup>–1</sup> <italic>vs</italic> 1.8 x10<sup>5</sup> Ms<sup>–1</sup>, and <italic>k</italic><sub>d</sub>s were 1.0x10<sup>–2</sup> Ms<sup>–1</sup> <italic>vs</italic> 2.3 x10<sup>–5</sup> Ms<sup>–1</sup> (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <italic>Top</italic>). As a result, SAM-Obz(Y101L)/HetFc-SDF-1α increased the binding avidity by 234 folds in comparison with the mother antibody. We asked whether the enhanced binding avidity observed for SAM-Obz(Y101L)/HetFc-SDF-1α could be reproduced in binding to SU-DHL5, a cell line derived from diffuse large B-cell lymphoma that overexpresses CD20. Flow cytometric analysis showed that SAM-Obz(Y101L)/HetFc-SDF-1α bound to the SU-DHL5 cell much more effectively than Obinutuzumab(Y101L) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <italic>Bottom</italic>). This result indicates that the SAM-Obz(Y101L)/HetFc-SDF-1α molecules were likely catenated on the surface of the SU-DHL5 cell. Together, these data demonstrate that noncovalent antibody catenation on a target surface is a way to greatly enhance antigen-binding avidity.</p></sec><sec id="s2-6"><title>Incidental observations</title><p>The homodimeric glCV30-SDF-1α construct showed three eluted fractions from a size-exclusion column: a void, a broad peak, and a narrow peak fraction (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). The narrow peak fraction was a mixture of the L chain and H chain missing the catenator as a result of partial proteolytic cleavage. In contrast, the broad peak did not contain the cleaved H chain. The broad peak fraction was highly soluble, as it could be concentrated at least to 200 μM. Assuming that the broad peak fraction was in a dynamic equilibrium between monomeric and oligomeric species in solution as a result of the weak intermolecular interaction of SDF-1α, we used it to assess their ability to enhance the binding avidity for the target antigens. glCV30-SDF-1α also exhibited association-dissociation kinetics similar to those of the dual catenator-fused antibodies: a similar <italic>k</italic><sub>a</sub> but very low <italic>k</italic><sub>d</sub> in comparison with those of the mother antibody (<xref ref-type="fig" rid="fig7">Figure 7</xref>). glCV30-SDF-1α exhibited virtually no dissociation and enhanced the binding avidity by at least 5120 folds (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Analyses of glCV30-SDF-1α.</title><p>(<bold>A</bold>) Elution profile and SDS-PAGE analysis of glCV30-SDF-1α. (<bold>B</bold>) The BLI runs shown on the left of <xref ref-type="fig" rid="fig5">Figure 5C</xref> are reused here for easy comparison with those for glCV30-SDF-1α. The <italic>K</italic><sub>D</sub> values could not be accurately determined due to instrumental insensitivity (<italic>K</italic><sub>D</sub> &lt;10 pM). The affinity-matured version, CV30, was analyzed and its BLI sensorgrams are shown on the right. (<bold>C</bold>) Neutralization of VSV virus pseudotyped with the SARS-CoV-2 spike protein. Each of the three antibodies was serially diluted and added to the rVSV-ΔG-Luc bearing the SARS-CoV-2 Spike protein of the Wuhan-Hu-1 strain. The mixture was incubated with HEK293T-hACE2 cells and the luciferase activity was measured. The geometric mean titer (GMT) values with a 95% confidence interval are shown on the right, which corresponds to the IC<sub>50</sub> values of 0.25, 3.22 and 0.21 μg/ml of CV30, glCV30 and glCV30-SDF-1α, respectively.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>SDS-PAGE result for glCV30-SDF-1α.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81646-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-fig7-v1.tif"/></fig><p>Consistently, the glCV30-SDF-1α construct exhibited notable activity in a virus neutralization assay using vesicular stomatitis virus (VSV) pseudotyped with the SARS-CoV-2 Spike protein. This virus is expected to harbor multiple copies of the Spike protein on its envelope. In comparison with glCV30, glCV30-SDF-1α exhibited a~15 fold lower inhibition constant 50 (IC<sub>50</sub>) value. This neutralization potency of glCV30-SDF-1α (IC<sub>50</sub> of 0.21 μg/ml) is comparable to that (IC<sub>50</sub> of 0.25 μg/ml) of CV30, which is an affinity-matured version of glCV30 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). CV30 bound to the RBD domain with the <italic>K</italic><sub>D</sub> of less than 10 pM in our measurement by BLI, similarly as glCV30-SDF-1α did (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p><p>We believe that the avidity enhancement and the strong neutralization activity of glCV30-SDF-1α reflect not only the catenation effect but also reversible oligomerization in solution, which further increases the binding avidity. Likely, some fraction of SDF-1α underwent a structural change at the low pH step in the protein purification, leading to reversible heterogeneous oligomerization. Although it is yet unclear why the reversible oligomerization, if this is the case, didn’t enhance the association rate constant, these incidental observations suggest a possible approach for producing noncovalent IgG antibody multimers that could enhance the sensitivity of diagnostic antibodies.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the current phage display for antibody screening, many candidates that do not satisfy a required affinity for a target antigen are rejected, although they might have high specificity of binding. A simple and general way of increasing the antigen-binding affinity of antibodies would be highly valuable for various applications of antibodies. Taking advantage of the particular homodimeric structure of IgG antibodies, we put forth a concept to enhance the bivalent antigen-binding interaction by fusing a weakly homodimerizing protein to the C-terminus of Fc. The validity of the concept was tested by simulations based on an ABM and supported by experimental demonstrations.</p><p>Our ABM with the three postulated rules was the basis for predicting the enhancement of effective antigen-binding avidity. The model has caveats. First, the assumption of uniform density for the fused catenators within a sphere oversimplifies the dynamics of the catenators, which would highly depend on physical contexts, such as molecular orientations and potential intramolecular interaction with the antibody (<xref ref-type="bibr" rid="bib37">Zhou, 2001</xref>). Second, the binding sites representing antigens are fixed on a surface in our model, but in real situations, antigens move their positions, <italic>e.g</italic>., receptor molecules on cellular membranes (<xref ref-type="bibr" rid="bib27">Saxton and Jacobson, 1997</xref>). Advanced molecular dynamics simulations incorporated into the ABM would take account of these microscopic details to result in a more accurate prediction of the behaviors of the <sup>cat</sup>Ab molecules and the binding sites. Despite these caveats, the simulations provided valuable insights into the proper ranges of the antigen-binding avidity of an antibody and catenator-catenator binding affinity. According to the simulation, we adopted SDF-1α and SAM, as catenators, both of which are weakly homodimerizing proteins (<italic>K</italic><sub>D</sub> of 100–150 μM). When fused to antibodies, they resulted in great enhancement of the effective antigen-binding avidity of the antibodies, which was due to drastically reduced rate of dissociation of the fused antibody molecules from the immobilized antigens.</p><p>The ‘antibody catenation on a target surface’ method presented herein might find practical applications. First, it can be applied to therapeutic antibodies against viruses, which have multiple copies of target antigens on their surface. Second, it can be used for sandwich-type point-of-care biosensors in which a second antibody is catenated to increase the sensitivity of detection. Third, this method can be used to sense biomarkers that exist in a very low number on a target cell (e.g. copy number &lt;10), which requires an extremely high-binding avidity of a probe antibody. For this application, employing an antibody with high antigen-binding affinity (e.g. <italic>K</italic><sub>D</sub> &lt;1 nM) and a catenator with high homodimerization affinity (e.g. (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> &lt;1 μM), would be necessary to overcome the low proximity effect due to the scarcely present antigen molecules. Fourth, it might also be applied to antibody-based targeted cancer therapy where side effects arising from antibody binding to normal cells are a general problem. Since cancer-associated antigen molecules are lower in number on normal cells than they are on cancer cells, catenated anticancer antibodies would be concentrated on the surface of cancer cells, because the effective binding avidity of a <sup>cat</sup>Ab depends on the number of antigen molecules on a target surface. In particular, this approach would greatly reduce the intrinsic toxicity of antibody-drug conjugates that are widely used currently. Of note, a catenator fused to the C-terminus of Fc would not affect the effector function Fc through the Fcγ receptor-binding site and FcRn binding site on it.</p><p>While we demonstrated that dual catenator-fused heterodimeric IgGs can enhance binding avidity, a higher (or at least the same) catenation effect should be observed for the conventional homodimeric IgGs. To prevent the oligomer formation of the homodimeric IgGs or potential intramolecular homodimerization of the catenator, a more robust catenator has to be employed. Specifically, the ideal catenator should geometrically disallow intramolecular homodimerization, exhibit fast association kinetics, and be able to withstand the standard low pH purification step. On the other hand, our demonstration indicates that this approach can be applied to bispecific antibodies employing a heterodimeric Fc.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>MCMC simulation</title><p>Simulation runs were carried out in the three steps stated below with specification of the target surface, <italic>K</italic><sub>D</sub> (for antibody-antigen interaction), (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> (for catenator-catenator interaction) and <inline-formula><mml:math id="inf2"><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> (effective local concentration of the catenator). In all simulations, the number of <sup>cat</sup>Ab was far more than that of the binding sites, and therefore, the concentration of free <sup>cat</sup>Ab was assumed to be the same as that of total <sup>cat</sup>Ab (free <sup>cat</sup>Ab +antigen-bound <sup>cat</sup>Ab). Simulation parameters their set values are listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Simulation specifications.</title><p>The definition and values of the parameters used in the presented simulations are tabulated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameters</th><th align="left" valign="bottom">Description</th><th align="left" valign="bottom">Values</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="3"><bold>Specification of <sup>cat</sup>Ab</bold></td></tr><tr><td align="left" valign="bottom"><italic>K</italic><sub>D</sub></td><td align="left" valign="bottom">Dissociation constant of antibody</td><td align="left" valign="bottom">10 nM</td></tr><tr><td align="left" valign="bottom">(<italic>K</italic><sub>D</sub>)<sub>catenator</sub></td><td align="left" valign="bottom">Dissociation constant of catenator</td><td align="left" valign="bottom">10 nM-10 mM</td></tr><tr><td align="left" valign="bottom">[<sup>cat</sup>Ab]</td><td align="left" valign="bottom">Antibody concentration</td><td align="left" valign="bottom">1 nM</td></tr><tr><td align="left" valign="bottom"><italic>l</italic></td><td align="left" valign="bottom">Length of the flexible linker</td><td align="left" valign="bottom">6 nm</td></tr><tr><td align="left" valign="bottom"><italic>c</italic></td><td align="left" valign="bottom">Length of the catenator</td><td align="left" valign="bottom">2 nm</td></tr><tr><td align="left" valign="bottom"><italic>L</italic></td><td align="left" valign="bottom">Reach length (<italic>l+c/2</italic>)</td><td align="left" valign="bottom">7 nm</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Specification of the target surface</bold></td></tr><tr><td align="left" valign="bottom">N<sub>total_binding_sites</sub><break/>(in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>)</td><td align="left" valign="bottom">Number of antibody-binding sites</td><td align="left" valign="bottom">98–102</td></tr><tr><td align="left" valign="bottom">Connectivity number<break/>(in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>)</td><td align="left" valign="bottom">Number of possible catenation</td><td align="left" valign="bottom">3 (Hexagonal)<break/>4 (Square)<break/>6 (Triangular)</td></tr><tr><td align="left" valign="bottom"><italic>d</italic> (in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>)</td><td align="left" valign="bottom">Distance between adjacent binding sites</td><td align="left" valign="bottom">12 nm</td></tr><tr><td align="left" valign="bottom"><italic>L</italic><sub>surface</sub> (in <xref ref-type="fig" rid="fig4">Figure 4</xref>)</td><td align="left" valign="bottom">Surface area of the target surface</td><td align="left" valign="bottom">40 nm<sup>2</sup></td></tr><tr><td align="left" valign="bottom">Binding site density<break/>(in <xref ref-type="fig" rid="fig4">Figure 4</xref>)</td><td align="left" valign="bottom">Surface density of the binding sites</td><td align="left" valign="bottom">1.47–11.76<break/>(per 7x7 nm<sup>2</sup>)</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Specification of simulation</bold></td></tr><tr><td align="left" valign="bottom">Updates/MCMC step</td><td align="left" valign="bottom">Number of updates in one MCMC step</td><td align="left" valign="bottom">30,000–100,000</td></tr><tr><td align="left" valign="bottom">Sampling size</td><td align="left" valign="bottom">Number of sampling for a parameter set</td><td align="left" valign="bottom">1024</td></tr></tbody></table></table-wrap><sec id="s4-1-1"><title>Step 1. Initialization step</title><list list-type="order"><list-item><p>A specified 3D target surface is implemented by assigning binding sites to specific locations on the surface.</p></list-item><list-item><p>Each binding site is set to be unoccupied.</p></list-item></list></sec><sec id="s4-1-2"><title>Step 2. <italic>MCMC stochastic update</italic> step</title><p>The following sub-steps (1-3) are iterated sufficient times to ensure thermodynamic equilibration.</p><list list-type="order"><list-item><p>A random binding site <italic>BS1</italic> is chosen from the target surface.</p></list-item><list-item><p>The binding status of <italic>BS1</italic> is updated.</p><p>If <italic>BS1</italic> is unoccupied, its status is changed to the occupied status with the acceptance probability of max(1, <inline-formula><mml:math id="inf3"><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msup><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>).</p><p>If <italic>BS1</italic> is occupied, its status is changed to the unoccupied status with the acceptance probability of max(1, <inline-formula><mml:math id="inf4"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msup><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mfrac></mml:math></inline-formula>).</p></list-item><list-item><p>An occupied binding site <italic>BS2</italic> right next to <italic>BS1</italic> is picked on the target surface, and the catenation status of the pair (<italic>BS1</italic>, <italic>BS2</italic>) is updated.</p><p>If (<italic>BS1</italic>, <italic>BS2</italic>) is uncatenated, and if both <italic>BS1</italic> and <italic>BS2</italic> have an unengaged catenator, its status is changed to the catenation status with the acceptance probability of max(1, <inline-formula><mml:math id="inf5"><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>).</p><p>If (<inline-formula><mml:math id="inf6"><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf7"><mml:mi>B</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula> is catenated, its status is changed to the uncatenated status with the acceptance probability of max(1, <inline-formula><mml:math id="inf8"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></inline-formula>)</p></list-item></list></sec><sec id="s4-1-3"><title>Step 3. Sampling step</title><list list-type="order"><list-item><p>The update step is stopped, and the final status of the target surface is recorded.</p></list-item><list-item><p>The total number of occupied and unoccupied binding sites are counted.</p></list-item></list><p>The codes for the model system and simulations are available in MATLAB and available on <ext-link ext-link-type="uri" xlink:href="https://github.com/JinyeopSong/Antibody_ThermoCalc_JY">Github</ext-link> (copy archived at <xref ref-type="bibr" rid="bib31">Song, 2020</xref>). A detailed description is provided in Readme.</p></sec></sec><sec id="s4-2"><title>Preparation of antibodies and catenator-fused antibodies</title><p>For preparing SAM-Trz(2 m)/HetFc-SDF-1α, DNA fragments encoding the two heavy chains containing the knobs mutations or the holes mutations (<xref ref-type="bibr" rid="bib18">Leaver-Fay et al., 2016</xref>) were synthesized (IDT) and cloned into the pCEP4 vector (Invitrogen). The final cloned vectors were to express the knob H chain fused to SAM-(His)<sub>6</sub>, and the hole H chain fused to SDF-1α-MBP. The two vectors were amplified using the NucleoBond Xtra Midi kit (Macherey-Nagel) and introduced into the CHO-S cells (Gibco) together with the light chain-encoding vector. The transfected cells were grown in the ExpiCHO expression medium (Gibco) for seven days post-transfection. Cell cultured media were collected by centrifugation at 4 °C, filtered through 0.45 µm filters (Millipore), and loaded onto Ni-NTA resin (Thermo Scientific) and subsequently onto amylose resin (NEB). The MBP tag was cleaved by TEV protease. The MBP was intentionally used to remove homodimeric fraction. The antibody was further purified using a HiLoad 26/60 Superdex 200 gel-filtration column (Cytiva) equilibrated with a buffer solution containing 20 mM Tris-HCl (pH 7.5) and 150 mM NaCl. SAM-Trz(3 m)/HetFc-SDF-1α, SAM-Obinutuzumab(Y101L)/HetFc-SDF-1α and SAM-glCV30/HetFc-SDF-1α were prepared similarly.</p><p>For preparing the homodimeric glCV30-SDF-1α, each DNA fragment encoding heavy chain variable regions (V<sub>H</sub>) and light chain variable regions (V<sub>L</sub>) of glCV30 were synthesized (IDT) and cloned into the pCEP4 vector. DNA fragments of C<sub>H1</sub>-C<sub>H2</sub>-C<sub>H3</sub> of the gamma heavy chain and C<sub>L</sub> of the kappa-type light chain were inserted into the pCEP4 vector encodingV<sub>H</sub> or V<sub>L</sub>, and the resulting vectors were named glCV30 Hc and glCV30 Lc, respectively. DNA fragment encoding SDF-1α was synthesized (IDT) and cloned into the glCV30 Hc next to C<sub>H3</sub> of glCV30 with (G<sub>4</sub>S)<sub>2</sub> linker sequence (glCV30-SDF-1α Hc). The glCV30-SDF-1α Hc and glCV30 Lc vectors were introduced into the CHO-S cells (Gibco). The transfected cells were grown in the ExpiCHO expression medium (Gibco) for ten days post-transfection. The culture supernatant was diluted by the addition of a binding buffer (150 mM NaCl, 20  mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.0) to a 1:1 ratio, loaded onto an open column containing Protein A resin (Sino Biological), and eluted with an elution buffer (0.1 M glycine, pH 3.5). The eluent was immediately neutralized by a neutralizing buffer (1 M Tris-HCl, pH 8.5), and the antibodies were further purified using a HiLoad 26/60 Superdex 200 gel-filtration column. The cloning, protein production, and purification procedures for mother antibodies were virtually identical to those used for glCV30-SDF-1α.</p></sec><sec id="s4-3"><title>Bio-layer interferometry</title><p>BLI experiments were performed to measure dissociation constants using an Octet R8 (Sartorius). Biotinylated SARS-CoV-2 RBD (Acrobio system) or biotinylated Her2/ERBB2 (Sino Biological) was loaded to a streptavidin biosensor tip (Sartorius) for 120s or 180s. A baseline was determined by incubating the sensor with Kinetics Buffer (Sartorius) for 60s. Antibody samples at different concentrations went through the association phase for 240s or 480s, and the dissociation phase for 720s or 1080s. All reactions were carried out in the Kinetics Buffer (Satorius). The binding kinetics were analyzed using the Octet DataAnalysis 10.0 software (Sartorius) to deduce the kinetic parameters. Experiments were performed in triplicate for glCV30 and glCV30-SDF-1α and duplicate for Trastuzumab(N30A/H91A) and Trastuzumab(N30A/H91A)-SDF-1α.</p></sec><sec id="s4-4"><title>Cell-binding assay</title><p>Flow cytometry experiments were performed to compare the binding efficiencies of Obinutuzumab(Y101L) and SAM-Obz(Y101L)/HetFc-SDF-1α. The SU-DHL5 cell line (DSMZ) was used for the experiments. Cells were cultured in RPMI media (Sigma-Aldrich) containing 10% fetal bovine serum at 37 °C and under 5% CO<sub>2</sub>. The cells were subcultured every 2–3 days to maintain &gt;95% cell viability. After centrifugation, the cell pellet was resuspended in the PBS buffer containing 1% BSA (PBSF), and more than 2x10<sup>5</sup> cells per well were plated in 96-well round bottom plates containing 200 μL media. The cells were treated with the antibody samples at room temperature for 1 h, and washed three times using PBSF and resuspended in 200 μL of PBSF. Each well was analyzed using Cytoflex_Plate Loader (Beckman Coulter). The sample flow rate was 30 μL/min, and 15,000 cells were counted per well.</p></sec><sec id="s4-5"><title>Pseudovirus neutralization assay</title><p>To prepare of VSV pseudotyped with the SARS-CoV-2 Spike protein of the Wuhan-Hu-1 strain, HEK293T cells (ATCC) plated overnight previously at 3x10<sup>6</sup> cells in a 10 cm dish were transfected using calcium phosphate with 15 μg plasmid encoding the spike protein of SARS-CoV-2 with 18-residue deletion at the cytoplasmic tail. At 24 hr post-transfection, cells expressing the Spike protein were infected for 1 hr with recombinant VSV, in which G gene was replaced with a luciferase gene (rVSV-ΔG-Luc). The cells were washed three times with Dulbecco’s phosphate-buffered saline, and 7–10 mL of the same media with 10% FBS was added. At 24–48 hr post-infection, the culture media were harvested, filtered with a 0.45 μm filter, and then stored at –80 °C for neutralization assay. For the pseudovirus neutralization assay, serially diluted CV30, glCV30 and glCV30-SDF-1α antibodies were mixed with the pseudovirus solution for 1 hr, and the mixture was added to HEK293T cells expressing human ACE2 (HEK293T-hACE2; 3x104 cells per well in 96-well plate), which were previously seeded overnight. Cells were lysed with Passive Lysis Buffer (Promega, E1941) At 24 hr post-transfection, LAR II (Promega, E1501) was added to the lysate, and the luciferase activity was measured. The percent neutralization was normalized to uninfected cells (100% neutralization) and infected cells (0% neutralization), both in the absence of antibody. The IC50 titers were determined with the nonlinear curves of the log(antibody) versus normalized response using Prism v9 (GraphPad).</p></sec><sec id="s4-6"><title>Cell lines</title><p>The CHO-S (Gibco), SU-DHL5 (DMSZ), and HEK-293T (ATCC) cell lines were negative for mycoplasma. Additionally, the identity of the SU-DHL5 and HEK-293T cell lines was confirmed by Short Tandem Repeat profiling.</p></sec><sec id="s4-7"><title>Figure preparation</title><p>The computational models of an antibody and an antibody-catenator in <xref ref-type="fig" rid="fig1">Figure 1A</xref> were generated by using the ROSETTA software (<xref ref-type="bibr" rid="bib20">Leman et al., 2020</xref>), and are presented by PyMOL (<xref ref-type="bibr" rid="bib4">Delano, 2004</xref>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>co-inventors in a patent application covering the antibody catenation method presented in this article (10-2023-0067544, Republic of Korea)</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81646-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Github repository to generate simulation data for <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>.</title></caption><media xlink:href="elife-81646-code1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>MATLAB scripts reproducing all simulation result in the paper are provided as Source code 1 (and are also publicly available through a MIT License on <ext-link ext-link-type="uri" xlink:href="https://github.com/JinyeopSong/2022_AntibodyCatenatedOnSurface">GitHub</ext-link>, copy archived at <xref ref-type="bibr" rid="bib32">Song, 2022</xref>). All simulation data generated by the scripts are provided as Source data.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Samsung Research Funding &amp; Incubation Center of Samsung Electronics under Project Number SRFC-MA2002-06.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldeghaither</surname><given-names>DS</given-names></name><name><surname>Zahavi</surname><given-names>DJ</given-names></name><name><surname>Murray</surname><given-names>JC</given-names></name><name><surname>Fertig</surname><given-names>EJ</given-names></name><name><surname>Graham</surname><given-names>GT</given-names></name><name><surname>Zhang</surname><given-names>Y-W</given-names></name><name><surname>O’Connell</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Jablonski</surname><given-names>SA</given-names></name><name><surname>Weiner</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A mechanism of resistance to antibody-targeted immune attack</article-title><source>Cancer Immunology Research</source><volume>7</volume><fpage>230</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0266</pub-id><pub-id pub-id-type="pmid">30563830</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>G</given-names></name><name><surname>Mi</surname><given-names>Q</given-names></name><name><surname>Dutta-Moscato</surname><given-names>J</given-names></name><name><surname>Vodovotz</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Agent-based models in Translational systems biology</article-title><source>Wiley Interdisciplinary Reviews. Systems Biology and Medicine</source><volume>1</volume><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1002/wsbm.45</pub-id><pub-id pub-id-type="pmid">20835989</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>PJ</given-names></name><name><surname>Lazar</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Next generation antibody drugs: Pursuit of the 'high-hanging fruit</article-title><source>Nature Reviews. Drug Discovery</source><volume>17</volume><fpage>197</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.227</pub-id><pub-id pub-id-type="pmid">29192287</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delano</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Use of PYMOL as a communications tool for molecular science</article-title><source>Abstracts of Papers of the American Chemical Society</source><volume>228</volume><fpage>U313</fpage><lpage>U314</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0103947</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>SS</given-names></name><name><surname>Clemmons</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Obinutuzumab: A novel anti-Cd20 Monoclonal antibody for chronic lymphocytic leukemia</article-title><source>Journal of the Advanced Practitioner in Oncology</source><volume>6</volume><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.6004/jadpro.2015.6.4.7</pub-id><pub-id pub-id-type="pmid">26705497</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foreman</surname><given-names>KW</given-names></name><name><surname>Vilar</surname><given-names>JMG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A general model for predicting the binding affinity of Reversibly and irreversibly Dimerized ligands</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0188134</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0188134</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Coevolutionary Dynamics of opinions and networks: From diversity to uniformity</article-title><source>Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics</source><volume>78</volume><elocation-id>016104</elocation-id><pub-id pub-id-type="doi">10.1103/PhysRevE.78.016104</pub-id><pub-id pub-id-type="pmid">18764017</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goydel</surname><given-names>RS</given-names></name><name><surname>Rader</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antibody-based cancer therapy</article-title><source>Oncogene</source><volume>40</volume><fpage>3655</fpage><lpage>3664</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01811-8</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grazzini</surname><given-names>J</given-names></name><name><surname>Richiardi</surname><given-names>MG</given-names></name><name><surname>Tsionas</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Bayesian estimation of agent-based models</article-title><source>Journal of Economic Dynamics and Control</source><volume>77</volume><fpage>26</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.jedc.2017.01.014</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansel</surname><given-names>TT</given-names></name><name><surname>Kropshofer</surname><given-names>H</given-names></name><name><surname>Singer</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>JA</given-names></name><name><surname>George</surname><given-names>AJT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The safety and side effects of Monoclonal antibodies</article-title><source>Nature Reviews Drug Discovery</source><volume>9</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nrd3003</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>WK</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Monte Carlo sampling methods using Markov chains and their applications</article-title><source>Biometrika</source><volume>57</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1093/biomet/57.1.97</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogarth</surname><given-names>PM</given-names></name><name><surname>Pietersz</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond</article-title><source>Nature Reviews. Drug Discovery</source><volume>11</volume><fpage>311</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/nrd2909</pub-id><pub-id pub-id-type="pmid">22460124</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenboom</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Selecting and screening recombinant antibody libraries</article-title><source>Nature Biotechnology</source><volume>23</volume><fpage>1105</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1038/nbt1126</pub-id><pub-id pub-id-type="pmid">16151404</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooten</surname><given-names>MB</given-names></name><name><surname>Wikle</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Statistical agent-based models for discrete Spatio-temporal systems</article-title><source>Journal of the American Statistical Association</source><volume>105</volume><fpage>236</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1198/jasa.2009.tm09036</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurlburt</surname><given-names>NK</given-names></name><name><surname>Seydoux</surname><given-names>E</given-names></name><name><surname>Wan</surname><given-names>Y-H</given-names></name><name><surname>Edara</surname><given-names>VV</given-names></name><name><surname>Stuart</surname><given-names>AB</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Suthar</surname><given-names>MS</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for potent neutralization of SARS-Cov-2 and role of antibody affinity maturation</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5413</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19231-9</pub-id><pub-id pub-id-type="pmid">33110068</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X-R</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Bergelson</surname><given-names>S</given-names></name><name><surname>Arroll</surname><given-names>T</given-names></name><name><surname>Parekh</surname><given-names>B</given-names></name><name><surname>May</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Strouse</surname><given-names>R</given-names></name><name><surname>Mire-Sluis</surname><given-names>A</given-names></name><name><surname>Schenerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Advances in the assessment and control of the Effector functions of therapeutic antibodies</article-title><source>Nature Reviews. Drug Discovery</source><volume>10</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nrd3365</pub-id><pub-id pub-id-type="pmid">21283105</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukuk</surname><given-names>L</given-names></name><name><surname>Dingley</surname><given-names>AJ</given-names></name><name><surname>Granzin</surname><given-names>J</given-names></name><name><surname>Nagel-Steger</surname><given-names>L</given-names></name><name><surname>Thiagarajan-Rosenkranz</surname><given-names>P</given-names></name><name><surname>Ciupka</surname><given-names>D</given-names></name><name><surname>Hänel</surname><given-names>K</given-names></name><name><surname>Batra-Safferling</surname><given-names>R</given-names></name><name><surname>Pacheco</surname><given-names>V</given-names></name><name><surname>Stoldt</surname><given-names>M</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Beer-Hammer</surname><given-names>S</given-names></name><name><surname>Willbold</surname><given-names>D</given-names></name><name><surname>Koenig</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structure of the Sly1 SAM Homodimer reveals a new interface for SAM domain self-Association</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-37185-3</pub-id><pub-id pub-id-type="pmid">30631134</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Froning</surname><given-names>KJ</given-names></name><name><surname>Atwell</surname><given-names>S</given-names></name><name><surname>Aldaz</surname><given-names>H</given-names></name><name><surname>Pustilnik</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Hassanali</surname><given-names>S</given-names></name><name><surname>Chamberlain</surname><given-names>AK</given-names></name><name><surname>Fitchett</surname><given-names>JR</given-names></name><name><surname>Demarest</surname><given-names>SJ</given-names></name><name><surname>Kuhlman</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Computationally designed Bispecific antibodies using negative state Repertoires</article-title><source>Structure</source><volume>24</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.02.013</pub-id><pub-id pub-id-type="pmid">26996964</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C-H</given-names></name><name><surname>Romain</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Charab</surname><given-names>W</given-names></name><name><surname>Todorova</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Triplett</surname><given-names>K</given-names></name><name><surname>Donkor</surname><given-names>M</given-names></name><name><surname>Lungu</surname><given-names>OI</given-names></name><name><surname>Lux</surname><given-names>A</given-names></name><name><surname>Marshall</surname><given-names>N</given-names></name><name><surname>Lindorfer</surname><given-names>MA</given-names></name><name><surname>Goff</surname><given-names>OR-L</given-names></name><name><surname>Balbino</surname><given-names>B</given-names></name><name><surname>Kang</surname><given-names>TH</given-names></name><name><surname>Tanno</surname><given-names>H</given-names></name><name><surname>Delidakis</surname><given-names>G</given-names></name><name><surname>Alford</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>RP</given-names></name><name><surname>Nimmerjahn</surname><given-names>F</given-names></name><name><surname>Varadarajan</surname><given-names>N</given-names></name><name><surname>Bruhns</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Igg FC domains that bind C1Q but not Effector FC gamma receptors delineate the importance of complement-mediated Effector functions (Vol 18, PG 889, 2017)</article-title><source>Nature Immunology</source><volume>18</volume><elocation-id>1173</elocation-id><pub-id pub-id-type="doi">10.1038/ni1017-1173c</pub-id><pub-id pub-id-type="pmid">28926542</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leman</surname><given-names>JK</given-names></name><name><surname>Weitzner</surname><given-names>BD</given-names></name><name><surname>Lewis</surname><given-names>SM</given-names></name><name><surname>Adolf-Bryfogle</surname><given-names>J</given-names></name><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Alford</surname><given-names>RF</given-names></name><name><surname>Aprahamian</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Barlow</surname><given-names>KA</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Basanta</surname><given-names>B</given-names></name><name><surname>Bender</surname><given-names>BJ</given-names></name><name><surname>Blacklock</surname><given-names>K</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Boyken</surname><given-names>SE</given-names></name><name><surname>Bradley</surname><given-names>P</given-names></name><name><surname>Bystroff</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Correia</surname><given-names>BE</given-names></name><name><surname>Coventry</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>De Jong</surname><given-names>RM</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Dsilva</surname><given-names>L</given-names></name><name><surname>Dunbrack</surname><given-names>R</given-names></name><name><surname>Ford</surname><given-names>AS</given-names></name><name><surname>Frenz</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>DY</given-names></name><name><surname>Geniesse</surname><given-names>C</given-names></name><name><surname>Goldschmidt</surname><given-names>L</given-names></name><name><surname>Gowthaman</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>JJ</given-names></name><name><surname>Gront</surname><given-names>D</given-names></name><name><surname>Guffy</surname><given-names>S</given-names></name><name><surname>Horowitz</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>P-S</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Jacobs</surname><given-names>TM</given-names></name><name><surname>Jeliazkov</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>DK</given-names></name><name><surname>Kappel</surname><given-names>K</given-names></name><name><surname>Karanicolas</surname><given-names>J</given-names></name><name><surname>Khakzad</surname><given-names>H</given-names></name><name><surname>Khar</surname><given-names>KR</given-names></name><name><surname>Khare</surname><given-names>SD</given-names></name><name><surname>Khatib</surname><given-names>F</given-names></name><name><surname>Khramushin</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>IC</given-names></name><name><surname>Kleffner</surname><given-names>R</given-names></name><name><surname>Koepnick</surname><given-names>B</given-names></name><name><surname>Kortemme</surname><given-names>T</given-names></name><name><surname>Kuenze</surname><given-names>G</given-names></name><name><surname>Kuhlman</surname><given-names>B</given-names></name><name><surname>Kuroda</surname><given-names>D</given-names></name><name><surname>Labonte</surname><given-names>JW</given-names></name><name><surname>Lai</surname><given-names>JK</given-names></name><name><surname>Lapidoth</surname><given-names>G</given-names></name><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Lindert</surname><given-names>S</given-names></name><name><surname>Linsky</surname><given-names>T</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Lubin</surname><given-names>JH</given-names></name><name><surname>Lyskov</surname><given-names>S</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><name><surname>Malmström</surname><given-names>L</given-names></name><name><surname>Marcos</surname><given-names>E</given-names></name><name><surname>Marcu</surname><given-names>O</given-names></name><name><surname>Marze</surname><given-names>NA</given-names></name><name><surname>Meiler</surname><given-names>J</given-names></name><name><surname>Moretti</surname><given-names>R</given-names></name><name><surname>Mulligan</surname><given-names>VK</given-names></name><name><surname>Nerli</surname><given-names>S</given-names></name><name><surname>Norn</surname><given-names>C</given-names></name><name><surname>Ó’Conchúir</surname><given-names>S</given-names></name><name><surname>Ollikainen</surname><given-names>N</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Pacella</surname><given-names>MS</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Pavlovicz</surname><given-names>RE</given-names></name><name><surname>Pethe</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Pilla</surname><given-names>KB</given-names></name><name><surname>Raveh</surname><given-names>B</given-names></name><name><surname>Renfrew</surname><given-names>PD</given-names></name><name><surname>Burman</surname><given-names>SSR</given-names></name><name><surname>Rubenstein</surname><given-names>A</given-names></name><name><surname>Sauer</surname><given-names>MF</given-names></name><name><surname>Scheck</surname><given-names>A</given-names></name><name><surname>Schief</surname><given-names>W</given-names></name><name><surname>Schueler-Furman</surname><given-names>O</given-names></name><name><surname>Sedan</surname><given-names>Y</given-names></name><name><surname>Sevy</surname><given-names>AM</given-names></name><name><surname>Sgourakis</surname><given-names>NG</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Siegel</surname><given-names>JB</given-names></name><name><surname>Silva</surname><given-names>D-A</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Szegedy</surname><given-names>M</given-names></name><name><surname>Teets</surname><given-names>FD</given-names></name><name><surname>Thyme</surname><given-names>SB</given-names></name><name><surname>Wang</surname><given-names>RY-R</given-names></name><name><surname>Watkins</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>L</given-names></name><name><surname>Bonneau</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Macromolecular modeling and design in Rosetta: Recent methods and Frameworks</article-title><source>Nature Methods</source><volume>17</volume><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0848-2</pub-id><pub-id pub-id-type="pmid">32483333</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liese</surname><given-names>S</given-names></name><name><surname>Netz</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Quantitative prediction of multivalent ligand-receptor binding affinities for influenza, cholera, and anthrax inhibition</article-title><source>ACS Nano</source><volume>12</volume><fpage>4140</fpage><lpage>4147</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b08479</pub-id><pub-id pub-id-type="pmid">29474056</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pharmacokinetics of Monoclonal antibodies and FC-fusion proteins</article-title><source>Protein &amp; Cell</source><volume>9</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s13238-017-0408-4</pub-id><pub-id pub-id-type="pmid">28421387</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLane</surname><given-names>AJ</given-names></name><name><surname>Semeniuk</surname><given-names>C</given-names></name><name><surname>McDermid</surname><given-names>GJ</given-names></name><name><surname>Marceau</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The role of agent-based models in wildlife Ecology and management</article-title><source>Ecological Modelling</source><volume>222</volume><fpage>1544</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/j.ecolmodel.2011.01.020</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzcar</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Heiland</surname><given-names>R</given-names></name><name><surname>Macklin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A review of cell-based computational modeling in cancer biology</article-title><source>JCO Clinical Cancer Informatics</source><volume>3</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1200/CCI.18.00069</pub-id><pub-id pub-id-type="pmid">30715927</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peckys</surname><given-names>DB</given-names></name><name><surname>Hirsch</surname><given-names>D</given-names></name><name><surname>Gaiser</surname><given-names>T</given-names></name><name><surname>de Jonge</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Visualisation of Her2 Homodimers in single cells from Her2 overexpressing primary formalin fixed Paraffin embedded tumour tissue</article-title><source>Molecular Medicine</source><volume>25</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/s10020-019-0108-z</pub-id><pub-id pub-id-type="pmid">31455202</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perc</surname><given-names>M</given-names></name><name><surname>Jordan</surname><given-names>JJ</given-names></name><name><surname>Rand</surname><given-names>DG</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Boccaletti</surname><given-names>S</given-names></name><name><surname>Szolnoki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Statistical physics of human cooperation</article-title><source>Physics Reports</source><volume>687</volume><fpage>1</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.physrep.2017.05.004</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>MJ</given-names></name><name><surname>Jacobson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Single-particle tracking: Applications to membrane Dynamics</article-title><source>Annual Review of Biophysics and Biomolecular Structure</source><volume>26</volume><fpage>373</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.26.1.373</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>AM</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antibody therapy of cancer</article-title><source>Nature Reviews Cancer</source><volume>12</volume><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nrc3236</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaga</surname><given-names>D</given-names></name><name><surname>Ellerman</surname><given-names>D</given-names></name><name><surname>Lombana</surname><given-names>TN</given-names></name><name><surname>Vij</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hristopoulos</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Shelton</surname><given-names>A</given-names></name><name><surname>Mai</surname><given-names>E</given-names></name><name><surname>Gadkar</surname><given-names>K</given-names></name><name><surname>Lo</surname><given-names>AA</given-names></name><name><surname>Koerber</surname><given-names>JT</given-names></name><name><surname>Totpal</surname><given-names>K</given-names></name><name><surname>Prell</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Spiess</surname><given-names>C</given-names></name><name><surname>Junttila</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Avidity-based binding to Her2 results in selective killing of Her2-overexpressing cells by anti-Her2/Cd3</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaat5775</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aat5775</pub-id><pub-id pub-id-type="pmid">30333240</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliwkowski</surname><given-names>MX</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antibody Therapeutics in cancer</article-title><source>Science</source><volume>341</volume><fpage>1192</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1126/science.1241145</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Antibody_Thermocalc_Jy</data-title><version designator="swh:1:rev:31176502e46198ce10ef8c2a974bf24961dcd32f">swh:1:rev:31176502e46198ce10ef8c2a974bf24961dcd32f</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:0e1edfb663cb3a155383c391528cb32d5ab2ccef;origin=https://github.com/Jinyeop3110/Antibody_ThermoCalc_JY;visit=swh:1:snp:bdd2e1e87cc98832764b9592adc4ffc63f2e2efd;anchor=swh:1:rev:31176502e46198ce10ef8c2a974bf24961dcd32f">https://archive.softwareheritage.org/swh:1:dir:0e1edfb663cb3a155383c391528cb32d5ab2ccef;origin=https://github.com/Jinyeop3110/Antibody_ThermoCalc_JY;visit=swh:1:snp:bdd2e1e87cc98832764b9592adc4ffc63f2e2efd;anchor=swh:1:rev:31176502e46198ce10ef8c2a974bf24961dcd32f</ext-link></element-citation></ref><ref id="bib32"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>2022_Antibodycatenatedonsurface</data-title><version designator="swh:1:rev:a0752960df17349802c536bc1693217549fe05a9">swh:1:rev:a0752960df17349802c536bc1693217549fe05a9</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:884f9bc7f465433ba5a70048a6d5d69aba16238a;origin=https://github.com/Jinyeop3110/2022_AntibodyCatenatedOnSurface;visit=swh:1:snp:8f1a1df6a585dd941c0f31cbcc8e39cd8fca76d0;anchor=swh:1:rev:a0752960df17349802c536bc1693217549fe05a9">https://archive.softwareheritage.org/swh:1:dir:884f9bc7f465433ba5a70048a6d5d69aba16238a;origin=https://github.com/Jinyeop3110/2022_AntibodyCatenatedOnSurface;visit=swh:1:snp:8f1a1df6a585dd941c0f31cbcc8e39cd8fca76d0;anchor=swh:1:rev:a0752960df17349802c536bc1693217549fe05a9</ext-link></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldkamp</surname><given-names>CT</given-names></name><name><surname>Peterson</surname><given-names>FC</given-names></name><name><surname>Pelzek</surname><given-names>AJ</given-names></name><name><surname>Volkman</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The monomer-Dimer equilibrium of Stromal cell-derived Factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin</article-title><source>Protein Science</source><volume>14</volume><fpage>1071</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1110/ps.041219505</pub-id><pub-id pub-id-type="pmid">15741341</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer Immunotherapies: From efficacy to resistance mechanisms - not only Checkpoint matters</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>690112</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.690112</pub-id><pub-id pub-id-type="pmid">34367148</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>LM</given-names></name><name><surname>Surana</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Monoclonal antibodies: Versatile platforms for cancer Immunotherapy</article-title><source>Nature Reviews. Immunology</source><volume>10</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nri2744</pub-id><pub-id pub-id-type="pmid">20414205</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>AL</given-names></name><name><surname>Dou</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>HTC</given-names></name><name><surname>Field</surname><given-names>VL</given-names></name><name><surname>Mockridge</surname><given-names>CI</given-names></name><name><surname>Moss</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>EL</given-names></name><name><surname>Booth</surname><given-names>SG</given-names></name><name><surname>French</surname><given-names>RR</given-names></name><name><surname>Potter</surname><given-names>EA</given-names></name><name><surname>Butts</surname><given-names>C</given-names></name><name><surname>Al-Shamkhani</surname><given-names>A</given-names></name><name><surname>Cragg</surname><given-names>MS</given-names></name><name><surname>Verbeek</surname><given-names>JS</given-names></name><name><surname>Johnson</surname><given-names>PWM</given-names></name><name><surname>Glennie</surname><given-names>MJ</given-names></name><name><surname>Beers</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fc gamma receptor dependency of Agonistic Cd40 antibody in lymphoma therapy can be overcome through antibody Multimerization</article-title><source>Journal of Immunology</source><volume>193</volume><fpage>1828</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303204</pub-id><pub-id pub-id-type="pmid">25024386</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H-X</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Loops in proteins can be modeled as worm-like chains</article-title><source>The Journal of Physical Chemistry B</source><volume>105</volume><fpage>6763</fpage><lpage>6766</lpage><pub-id pub-id-type="doi">10.1021/jp011355n</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81646.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Tony</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.12.499671" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.12.499671"/></front-stub><body><p>This important study documents the use of computational models and protein design to enhance antibody binding. The new method could have a broad and immediate impact on a variety of diagnostic procedures that use antibodies as sensitivity is often an issue in these kinds of experiments. The evidence produced is highly compelling through demonstration of the substantial sensitivity enhancement achieved in two test cases. This manuscript will likely be of interest to researchers who use antibodies for diagnostic and therapeutic purposes.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81646.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.12.499671">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.12.499671v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Noncovalent antibody catenation on a target surface drastically increases the antigen-binding avidity&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tony Ng as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Regarding experiments:</p><p>1) There needs to be a negative control for the affinity measurements, such as incorporating a dimerization-defective variant of the SDF-1alpha catenator and seeing if the avidity effect disappears.</p><p>2) The experimental assessment focuses solely on the binding affinity and no other aspects of the antibodies, such as purity and solution properties. If the catenator negatively impacts purification, that is information that should be included in the manuscript. The behavior of the antibodies in the solution is particularly important. You want the catenation to be highly dependent on the presence of the target antigen. The catenator could induce the antibodies to form an essentially infinite array and/or large aggregates. Aggregates tend to be highly immunogenic, so if any potential targets of this method are intended to be injected into animals or people, unwanted immune responses could be a serious issue. Gel filtration and dynamic light scattering are two potential methods that can assess the size of the antibodies +/- catenator and +/- antigen to ensure that the antibodies exhibit the desired behavior.</p><p>3) It should be stated that the two antibodies, Trastuzumab(N30A/H91A) and glCV30, were selected for weakened antigen-binding affinities.</p><p>4) On page 12, line 246, SDF-1α KD was 150 uM; on page 14, line 299, SDF-1α KD was 150 nM. Which one is correct?</p><p>5) What is the physiological expression and function of SDF-1α? Would injection of IgG fused with SDF-1α disturb the physiological function of SDF-1α?</p><p>6) What are the expression yields of catenator-fused antibodies? How do the yields compare to those of the unmodified antibodies?</p><p>7) It would greatly improve the implications of IgG catenation if relevant antibody functional assays can be performed for the two tested antibodies. For example, an in vitro assay to compare the function of Trastuzumab(N30A/H91A), cat-Trastuzumab(N30A/H91A), and Trastuzumab. Likewise, a SARS-CoV-2 neutralization assay to compare glCV30, cat-glCV30, and CV30.</p><p>Regarding computations:</p><p>8) The simulations could be improved. The third major step in the simulations seems to favor the binding ability of catenated IgGs. If so, in any means the simulations will yield a higher binding affinity for the catenated homodimeric IgG. This should be clarified.</p><p>9) What is the role of the concentration of IgGs on the binding behavior? Would it be possible somehow to include this in the simulations and also link it to the experiments?</p><p>10) While the results render the enhanced binding affinity of the catenated homodimeric IgGs, the study would benefit from a more elaborated interpretation and discussions of the results.</p><p>(10a) One interesting base of discussion may include how the fusion of the catenator may likely affect the binding behavior, the intrinsic binding behavior, and/or on the global structural changes of IgGs per se, beyond its proximity-driven contribution. Please refer both to the monomeric and homodimeric (catenated) forms. Would it lead to a more restricted structure in the mobility in the unbound states so as to decrease the entropic cost for the binding and thus increase the binding avidity/affinity (in addition to external proximity-driven association)? In other words, what would be the role of entropy in the free energy of binding, given that the enthalpic contributions remain the same? Possible effects of the length of the catenator should also in parts be related to the entropy. For example, if a longer and more flexible catenator is considered, what would the resulting observation be? Both experimentally and computationally.</p><p>(10b) On the other side, simple simulation approaches have a high value with a level of abstraction while still keeping the physical and biological relevance. In the simulations, i.e., in the sampling of various states, three main terms/rules to govern the behavior are implemented. One is a term favoring an increase in the ability to bind (preventing unbinding) to the surface upon the catenation of IgGs. This may need to be substantiated for the simulations not imposing a presumed ability to increase the binding (or decrease the unbinding) ability upon catenation.</p><p>(10c) The weakly homodimerizing state of the catenator appears as one of the important aspects of the proposed design strategy. Would it also be possible that the experimental observations may readily also imply the higher binding ability of the catenator fused IfgG without the homodimerization on the surface (due to the reduced entropic cost for the binding)? The presentation of the evidence of the homodimerization of the catenator and the catenated IgGs on the surface would strengthen the findings and discussions.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81646.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>1) There needs to be a negative control for the affinity measurements, such as incorporating a dimerization-defective variant of the SDF-1alpha catenator and seeing if the avidity effect disappears.</p></disp-quote><p>Employing the HetFc was quite instrumental in making a control construct, which is an antibody-catenator with only one arm, which cannot be catenated;</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-sa2-fig1-v1.tif"/></fig><p>Consistently, the avidity enhancement was not observed with this construct. The results are shown as Figure 6A in the revision.(*Both the single and the dual catenator-fused antibodies have mScarlet on the C-terminus of the light chain. The mScarlet fusion is for later cell-based experiments.)</p><disp-quote content-type="editor-comment"><p>2) The experimental assessment focuses solely on the binding affinity and no other aspects of the antibodies, such as purity and solution properties. If the catenator negatively impacts purification, that is information that should be included in the manuscript. The behavior of the antibodies in the solution is particularly important. You want the catenation to be highly dependent on the presence of the target antigen. The catenator could induce the antibodies to form an essentially infinite array and/or large aggregates. Aggregates tend to be highly immunogenic, so if any potential targets of this method are intended to be injected into animals or people, unwanted immune responses could be a serious issue. Gel filtration and dynamic light scattering are two potential methods that can assess the size of the antibodies +/- catenator and +/- antigen to ensure that the antibodies exhibit the desired behavior.</p></disp-quote><p>The revised manuscript includes Figure 5B and C, Figure 6A and Figure 6—figure supplement 1, which show the purification process for the newly generated antibody-catenator constructs. The elution profiles from a size-exclusion column confirm that these constructs were monomeric in solution.</p><disp-quote content-type="editor-comment"><p>3) It should be stated that the two antibodies, Trastuzumab(N30A/H91A) and glCV30, were selected for weakened antigen-binding affinities.</p></disp-quote><p>We state that “The two antibodies were chosen based on their weak antigen-binding affinities.” (page 13, in the revision).</p><disp-quote content-type="editor-comment"><p>4) On page 12, line 246, SDF-1α KD was 150 uM; on page 14, line 299, SDF-1α KD was 150 nM. Which one is correct?</p></disp-quote><p>Thank you for the opportunity to correct our typographical error. 150 μM is correct, and nM is now corrected to μM.</p><disp-quote content-type="editor-comment"><p>5) What is the physiological expression and function of SDF-1α? Would injection of IgG fused with SDF-1α disturb the physiological function of SDF-1α?</p></disp-quote><p>SDF-1α belongs to the chemokine family, members of which activate leukocytes and are induced by proinflammatory stimuli. The first 7 N-terminal residues are known to serve as a receptor-binding site for CXCR4 [EMBO J. 1997;16:6996–7007]. It should be confirmed that SDF-1α or its variants (e.g., the N-terminal deletion mutant) do not cause a side effect, if SDF-1α would be used for therapeutic purposes.</p><disp-quote content-type="editor-comment"><p>6) What are the expression yields of catenator-fused antibodies? How do the yields compare to those of the unmodified antibodies?</p></disp-quote><p>On our hands, the total yield of the dual catenator-fused antibodies (~5 mg from 25 mL culture) was about half of the production of the mother antibodies. Usually, fusing a protein to IgG antibody reduces the production of the fused antibody, but the yield quite depends on the protein being fused, as far as I know.</p><disp-quote content-type="editor-comment"><p>7) It would greatly improve the implications of IgG catenation if relevant antibody functional assays can be performed for the two tested antibodies. For example, an in vitro assay to compare the function of Trastuzumab(N30A/H91A), cat-Trastuzumab(N30A/H91A), and Trastuzumab. Likewise, a SARS-CoV-2 neutralization assay to compare glCV30, cat-glCV30, and CV30.</p></disp-quote><p>We conducted a cell-binding experiment using flow cytometry, which demonstrates that SAM-Obinutuzumab(Y101L)/HetFc-SDF-1α binds to CD20-expressing cells (SU-DHL5 cell line) much more effectively than the mother antibody (Figure 6B, in the revision). A new author, Seonghoon Kim, was involved in the extension of our work to include Obinutuzumab.</p><p>In addition, pseudovirus (instead of SARS-CoV-2) neutralization assay was performed exactly as the reviewer commented, but with the old construct (glCV30-SDF-1α). glCV30-SDF-1α exhibited a ~15 fold lower IC<sub>50</sub> value in comparison with glCV30, which is comparable to that of CV30, having an extremely potent antigen-binding affinity (<italic>K</italic><sub>D</sub> of &lt; 0.01 nM). The result is now shown as Figure 7B. The description of this assay and the results are now stated under the subtitle of “Incidental observations” (pages 15-16, in the revision). The experimenters (Jae U. Jung and Chih-Jen Lai at the Cleveland Clinic) are included as authors in the revised version.</p><disp-quote content-type="editor-comment"><p>Regarding computations: (8) The simulations could be improved. The third major step in the simulations seems to favor the binding ability of catenated IgGs. If so, in any means the simulations will yield a higher binding affinity for the catenated homodimeric IgG. This should be clarified.</p></disp-quote><p>We agree with the review in that the third rule favors the binding ability of catenated IgGs, because it assumes that catenated antibodies are not allowed to dissociate from the binding site. While this assumption is not exactly correct, we think that it is valid, considering the behavior of a multivalent ligand. When the IgG portion dissociates completely from the binding site, it is still anchored by the catenation arm, and thus it will rebind the same binding site immediately. This postulation is supported by binding ΔG calculation presented as a response to comment 10b below, and agrees with the quantitative analysis showing that multivalent ligand exhibits orders of magnitude binding likelihood increase when the ligand size is comparable to the stretch length of a conjugating linker [Liese, S. and Netz, R. R., <italic>ACS Nano,</italic> 12<bold>,</bold> 4140 (2018)].</p><disp-quote content-type="editor-comment"><p>9) What is the role of the concentration of IgGs on the binding behavior? Would it be possible somehow to include this in the simulations and also link it to the experiments?</p></disp-quote><p>The binding site occupancy depends on [<sup>cat</sup>Ab]/<italic>K</italic><sub>D</sub>. Figure 4—figure supplement 2 shows the binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub> as a function of (<italic>K</italic><sub>D</sub>)<sub>catenator</sub>. In this simulation, [<sup>cat</sup>Ab] was fixed (10<sup>-9</sup> M) while <italic>K</italic><sub>D</sub> was varied (from 10<sup>-8</sup> to 10<sup>-6</sup>). In the figure legend and in the main text, we now explicitly state that <italic>K</italic><sub>D</sub> was varied from 10<sup>-8</sup> to 10<sup>-6</sup> (pages 12, 35 in the revision). To address this comment, we set <italic>K</italic><sub>D</sub> = 10 nM (as used for simulation in Figures 3 and 4), and varied [<sup>cat</sup>Ab] from 0.1 to 10 nM. The binding site occupancy and (<italic>K</italic><sub>D</sub>)<sub>eff</sub> as a function of [<sup>cat</sup>Ab] are plotted for three different set values of (<italic>K</italic><sub>D</sub>)<sub>catenator</sub> (1 μM, 10 μM and 100 μM). The new figures are now presented as Figure 4—figure supplement 3. This simulation shows that the enhancement of (<italic>K</italic><sub>D</sub>)<sub>eff</sub> by increasing the concentration of <sup>cat</sup>Ab is much less dramatic than that by increasing the affinity for catenator homodimerization. A new figure legend and describing sentences in the main text are added (page 12, in the revision).</p><disp-quote content-type="editor-comment"><p>10) While the results render the enhanced binding affinity of the catenated homodimeric IgGs, the study would benefit from a more elaborated interpretation and discussions of the results.</p></disp-quote><p>We have demonstrated the binding avidity enhancement by employing a heterodimeric Fc. Accordingly, the following discussion is now stated in the revision (pages 19-20, in the revision);</p><p>“While we demonstrated that dual catenator-fused heterodimeric IgGs can enhance binding avidity, the oligomer formation or potential intramolecular homodimerization of the catenator necessitates the development of a more robust catenator for application to conventional homodimeric IgGs. Specifically, the ideal catenator should geometrically disallow intramolecular homodimerization, exhibit fast association kinetics, and be able to withstand the standard low pH purification step. On the other hand, our demonstration indicates that this approach can be applied to bispecific antibodies employing a heterodimeric Fc.”</p><disp-quote content-type="editor-comment"><p>(10a) One interesting base of discussion may include how the fusion of the catenator may likely affect the binding behavior, the intrinsic binding behavior, and/or on the global structural changes of IgGs per se, beyond its proximity-driven contribution. Please refer both to the monomeric and homodimeric (catenated) forms. Would it lead to a more restricted structure in the mobility in the unbound states so as to decrease the entropic cost for the binding and thus increase the binding avidity/affinity (in addition to external proximity-driven association)? In other words, what would be the role of entropy in the free energy of binding, given that the enthalpic contributions remain the same? Possible effects of the length of the catenator should also in parts be related to the entropy. For example, if a longer and more flexible catenator is considered, what would the resulting observation be? Both experimentally and computationally.</p></disp-quote><p>To fully address this comment, we would need to consider the detailed molecular behavior of the IgG part, catenator and linker, probably using molecular dynamics simulation, which we think is outside the scope of the current work. We like to qualitatively describe what we think about the raised issues. Fused to the C-terminus of Fc, the catenator won’t affect the complementary determining region (CDR) of Fab which is located on the opposite side of the C-terminus of Fc. This notion is supported by the observation that all catenator-fused antibodies exhibited association kinetics similar to those of the mother antibodies (Figure 5).</p><p>Regarding the mobility of the structure, we presume that the fused catenator would not interact with the antibody portion and thus it would not affect the intrinsic structural mobility of the antibody.</p><p>Since the catenator is fused to the C-terminus of Fc by a flexible linker, the homodimerization of catenator would decrease the entropy upon catenation. However, the enthalpic contribution would overcome the entropic loss, and result in negative free energy of the catenator homodimerization.</p><p>Figure 2—figure supplement 1 (in the revision) shows the simulation for five different values of the reach length (<italic>R</italic>), which is the sum of the linker length and a half of the catenator length. The simulation results show that the likelihood of catenation decreases as the linker length increases over the distance (<italic>d</italic>) between the two adjacent <sup>cat</sup>Ab-2Ag complexes, while it is maximum when the reach length equals <italic>d</italic>. Since the catenator length is fixed, increasing the linker length (such that <italic>R</italic> &gt; <italic>d</italic>) will lower the catenation effect.</p><disp-quote content-type="editor-comment"><p>(10b) On the other side, simple simulation approaches have a high value with a level of abstraction while still keeping the physical and biological relevance. In the simulations, i.e., in the sampling of various states, three main terms/rules to govern the behavior are implemented. One is a term favoring an increase in the ability to bind (preventing unbinding) to the surface upon the catenation of IgGs. This may need to be substantiated for the simulations not imposing a presumed ability to increase the binding (or decrease the unbinding) ability upon catenation.</p></disp-quote><p>This comment is nearly the same as comment 8 above about the restricted dissociation of catenated antibody molecules from the binding site. We did rough calculations of entropy changes in the binding of uncatenated antibody and catenated antibody to the binding site. The largest difference in entropic change originates from a change in configurational entropy, <italic>i.e</italic>, by the change in volume that an anibody molecule can sample.</p><p>(1) Entropy of an uncatenated antibody:</p><p>A free antibody can sample an entire volumetric space. The per-particle entropy of N identical molecules in volume V is calculated as: <inline-formula><mml:math id="sa2m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mi>S</mml:mi><mml:mi>N</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mi>V</mml:mi><mml:mi>N</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mi>m</mml:mi><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>5</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> Therefore, the per-particle entropy is a function of [<sup>cat</sup>Ab] and temperature T.<inline-formula><mml:math id="sa2m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mo fence="false" stretchy="false">[</mml:mo><mml:mrow><mml:mtext>cat</mml:mtext></mml:mrow></mml:msup><mml:mtext>Ab</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msup><mml:mo fence="false" stretchy="false">[</mml:mo><mml:mrow><mml:mtext>cat</mml:mtext></mml:mrow></mml:msup><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mo fence="false" stretchy="false">]</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>5</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> (2) Entropy of a catenated antibody :</p><p>A catenated Ab has smaller configurational entropy as it is anchored by the linker and thus confined in a smaller space. We approximate the sample space as a sphere with the radius twice the stretched reach length (2L). Additional entropic effect by the linker is neglected, since the IgG portion has a much larger molecular mass. Then the entropy of a catenated antibody is as follows.</p><p><inline-formula><mml:math id="sa2m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mfrac><mml:mtable rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mi>V</mml:mi><mml:mo>∗</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>m</mml:mi><mml:mi>k</mml:mi><mml:mi>T</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msup></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&lt;</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;&lt;</mml:mo><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mtext> </mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>&lt;</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;&lt;</mml:mo><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:msubsup><mml:mi>h</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>32</mml:mn><mml:mi>π</mml:mi></mml:mrow><mml:mn>3</mml:mn></mml:mfrac><mml:msup><mml:mi>L</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> Under the simulation scheme, for <inline-formula><mml:math id="sa2m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="sa2m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mo fence="false" stretchy="false">[</mml:mo><mml:mrow><mml:mtext>cat</mml:mtext></mml:mrow></mml:msup><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mo fence="false" stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>M</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mn>300</mml:mn><mml:mtext> </mml:mtext><mml:mi>K</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="sa2m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>−</mml:mo><mml:mn>15</mml:mn><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, <italic>T</italic>Δ<italic>S</italic> as a function of linker length was calculated and a plot is shown in <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81646-sa2-fig2-v1.tif"/></fig><p>Under the assumption that enthalpic contributions remain the same, the free energy changes for antibody (Ab) are <inline-formula><mml:math id="sa2m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>bound\ Ab</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mtext>free\ Ab</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mtext>Tln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1.37</mml:mn><mml:mfrac><mml:mtext>kcal</mml:mtext><mml:mtext>mol</mml:mtext></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> (uncatenated)</p><p><inline-formula><mml:math id="sa2m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mtext>bound\ Ab</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mtext>free\ Ab</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mtext>Tln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>7.30</mml:mn><mml:mfrac><mml:mtext>kcal</mml:mtext><mml:mtext>mol</mml:mtext></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula> (Catenated)</p><p>Therefore, about 10% of monomeric antibody molecules bind to the binding site, whereas more than 99% of catenated antibody molecules bind to the binding site. The above calculation implies that configurational entropic change is sufficient to account for the order of magnitude difference in the binding avidity between monomeric antibody and catenated antibody in our simulations.</p><disp-quote content-type="editor-comment"><p>(10c) The weakly homodimerizing state of the catenator appears as one of the important aspects of the proposed design strategy. Would it also be possible that the experimental observations may readily also imply the higher binding ability of the catenator fused IfgG without the homodimerization on the surface (due to the reduced entropic cost for the binding)? The presentation of the evidence of the homodimerization of the catenator and the catenated IgGs on the surface would strengthen the findings and discussions.</p></disp-quote><p>This comment is in line with comment (2). We constructed SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc having one catenator arm. This antibody did not show avidity enhancement, in contrast with SAM-Trastuzumab(N30A/H91A/Y100A)/HetFc-SDF-α, having two catenator arms. The results are shown in Figure 6A in the revision.</p></body></sub-article></article>